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1. Abstract  
BACKGROUND: Some epidemiologic studies have suggested inverse relations 
between intake of dairy products and components of the metabolic syndrome. 
OBJECTIVE: The objective was to investigate the effects of an increased intake of 
dairy products in persons, with a habitually low intake of dairy products and with 
traits of the metabolic syndrome, on body composition and factors related to the 
metabolic syndrome. 
STUDY DESIGN: Middle-aged overweight subjects (n = 38) with traits of the 
metabolic syndrome were recruited at the Lipid Clinic, Rikshospitalet Oslo University 
and randomly assigned into milk or control groups. The milk group was instructed to 
consume at least 3 portions of low- to moderate-fat dairy products daily. The control 
group maintained their habitual diet. Clinical investigations were conducted at 
baseline and after the six months intervention period. 
RESULTS: There were no significant differences between changes in body weight or 
body composition, blood pressure, markers of inflammation, adiponectin, or oxidative 
stress between the milk and the control groups. There was a significantly decrease in 
E-selectin, a marker of endothelial function in the milk group at the end of the study 
compared to the control group (P = 0.008). Among participants with a low calcium 
intake at baseline (<700 mg/d), there was a significant treatment effect for waist 
circumference (P = 0.023).  
CONCLUSIONS: This study gives no clear support to the hypothesis that a 
moderately increased intake of dairy products beneficially affects aspects of the 
metabolic syndrome. The apparently positive effects on waist circumference in 
subjects with a low calcium intake suggest a possible threshold in relation to effects 
on body composition. 
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2. Introduction  
2.1 Master thesis as part of a multicentre study 
This master thesis is based on an intervention study undertaken at the Lipid Clinic, 
Rikshospitalet, Oslo University Hospital between January 2005 and July 2007. the 
study was part of a multi-centre Nordic study, with participating centres in Helsinki, 
Uppsala and Oslo. The results of the Nordic study as a whole were published in 2009 
and is attached in full-text in this thesis for reference (Appendix 1).  
2.2 Metabolic syndrome 
2.2.1 Definition 
The Metabolic Syndrome is defined as a clustering of cardiovascular risk factors; 
including (abdominal) obesity, hypertension, dyslipidaemia (elevated triglycerides and 
decreased HDL-cholelsterol levels) and hyperglycaemia (impaired glucose 
metabolism) (1). 
The concept of metabolic syndrome has existed since 1920, when the two Austrian 
physicians (Karl Hitzenberger and Martin Richter-Quittner) and the Spaniard 
Gregorio Marañón observed the relationship between blood pressure and diabetes 
mellitus in some of their patients. At about the same time, Kylin described the 
hypertension-hyperglycaemia-hyperuricaemia syndrome. In 1947, Vague drew 
attention to upper body adiposity as the obesity phenotype that was commonly 
associated with metabolic abnormalities in patients with type 2diabetes and CVD. In 
1988, Reaven described the "Syndrome X". He formed the hypothesis that insulin 
resistance is the common etiological factor for a group of disorders, consisting of 
impaired glucose tolerance, hyperinsulinaemia, dyslipidaemia and hypertension. The 
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metabolic syndrome has also been referred as the "deadly quarter" or the insulin 
resistance syndrome (2,3). 
There are several different definitions of the MS, and the various cut-off for its 
components varies widely. The first official definition of MS was established in 1999 
by the World Health Organisation (WHO). Later followed definitions defined by 
European Group for Study of Insulin Resistance (EGIR) (4) and the National 
Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) in 2001 
(5). 
The WHO and EGIR definitions both consider insulin resistance (or glucose 
intolerance) as an essential for diagnosis of MS. This is in contrast to the ATP III 
definition that regards insulin resistance as only one of several criteria. The WHO 
definition was developed for epidemiological purposes, while the ATP III definition 
was intended, due to its simplicity in use, for alerting clinicians to subjects at risk, and 
it is to date the most commonly used in clinical practice.  
More recent definitions include those issued by the American Heart Association and 
National Heart, Lung, and Blood Institute (AHA/NHLBI) (5,6,6) and the International 
Diabetes Federation (IDF) (7). The AHA/NHLBI modified the ATP III by reducing 
the threshold for hyperglycemia and some other minor modifications The IDF 
definition further modified the ATP III definition and aimed to unify the different 
definitions. The IDF definition considered central obesity (measured by waist 
circumference) as essential for diagnosis and was the first definition to include 
different cut-points of central obesity according to different ethnic groups. The 
threshold for waist circumference in the IDF definition was generally lower than in 
the preceding ATP III definition (the IDF definition required central obesity plus any 
two of four components: elevated triglycerides, low HDL-cholesterol, hypertension 
and elevated plasma glucose). 
In 2009, Alberti K.G. et al. presented consensus criteria from the IDF and 
AHA/NHLBI which propose diagnosis of metabolic syndrome by using any 3 of 5 
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criteria (waist circumference, hypertension, increased plasma glucose, increased 
triglycerides and decreased HDL-cholesterol (8). 
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Figure 1: Metabolic Syndrome definitions 
 WHO (1999) EGIR (1999) NCEP ATP III (2001) 
 
 
 
 
 
 
 
 
Fasting plasma 
glucose 
 
Blood pressure 
 
Triglycerides 
 
 
 
 
HDL-cholesterol 
 
 
Obesity 
 
 
 
 
 
 
 
Microalbuminuria 
Glucose intolerance, IGT or 
diabetes and/ or insulin 
resistance* plus two or 
more of the following: 
 
 
 
 
 
 
 
≥ 140/90 mmHg  
 
Raised plasma 
triglycerides: ≥ 1.7 mmol/l 
(150 mg/dl) and/ or 
 
 
Men: < 0.9 mmol/l (35 
mg/dl) 
Women: < 1.0 mmol/l (39 
mg/dl) 
 
Men:  
waist-hip ratio > 0.90 
Women:  
waist-hip ratio > 0.85  
 
and/ or BMI > 30 kg/m2  
 
Urinary albumin excretion 
rate ≥ 20 µg/ min or 
albumin:creatinine ratio ≥ 
30 mg/ g 
Insulin resistance (defined as 
hyperinsulinaemia – top 25% 
of fasting insulin values 
among the non-diabetic 
population) 
  
Plus two of the following : 
 
≥ 6.1 mmol/l (110 mg/ dl) but 
non-diabetic 
 
≥ 140/ 90 mmHg or treatment 
 
> 2.0 mmol/l (178 mg/ dl) or 
treatment and/ or  
 
 
 
< 1.0 mmol/l (39 mg/ dl) or 
treatment 
 
 
Men:  
waist circumference ≥ 94 cm  
Women:  
waist circumference ≥ 80 cm  
Three or more of the following 
five risk factors:  
 
 
 
≥ 5.6 mmol/l (00 mg/ dl)a 
 
≥ 130/≥85 mmHg 
 
≥ 1.7 mmol/l (150 mg/ dl) 
 
 
 
Men: < 1.03 mmol/l (40 mg/ 
dl) 
Women: <1.29 mmol/l (50 mg/ 
dl) 
 
Men: waist circumference > 
102 cmb  
Women: waist circumference > 
88 cm 
*Insulin sensitivity measured under hyperinsulinaemic euglycaemic conditions, glucose uptake below lowest quartile 
for background population under investigation.  
aThe 2001 definition identified fasting plasma glucose of ≥ 6.1 mmol/l (110 mg/ dl) as elevated. This was modified in 
2004 to be ≥ 5.6 mmol/l (100 mg/dl), in accordance with the American Diabetes Association’s updated definition of 
impaired fasting glucose (IFG). 
bSome male patients can develop multiple metabolic risk factors when the waist circumference is only marginally 
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2.2.2 Prevalence 
Prevalence of metabolic syndrome worldwide  
The prevalence of MS is increasing worldwide as is also the prevalence of obesity. 
Just as the prevalence of the individual components of the syndrome varies among 
populations, so does the prevalence of the metabolic syndrome itself (9). Differences 
in genetic background, diet, levels of physical activity, population age and sex 
structure, ethnicity and levels of over- and undernutrition all influence the prevalence. 
The prevalence also varies according to the definition of metabolic syndrome used 
(from 1 to 39%). Definitions with lower cut-offs for waist-circumference, for 
instance, will diagnose a larger group of people with metabolic syndrome. 
Regardless of the differences in definitions and in the design of the studies that has 
investigated the prevalence certain inferences can be made (9). In all countries the 
prevalence of metabolic syndrome seems to increase with age, and there is wide 
variation in prevalence in both sexes (9). However, the prevalence seems to decline in 
the oldest population (10). Cultural factors are also important and metabolic syndrome 
is becoming more prevalent in developing countries in the Middle East (10). 
For large scale screening purposes, NCEP/ATP classification is more practical than 
the WHO criteria, since determination of fasting glucose is sufficient and 
determination of insulin resistance levels is not required. In both definitions, the 
presence of type 2 diabetes does not exclude metabolic syndrome.  
In European countries, the prevalence varies from 4–36% depending on age and 
definition of MS (10). 
Hu G. et al (11) reviewed 11 European study cohorts and found that 15.7% of men 
and 14.2% of women had the metabolic synrome as defined by the modified WHO 
definition (hyperinsulinaemia plus two or more other components including obesity, 
hypertension, dyslipidaemia, and impaired glucose regulation). When the syndrome 
was defined by the presence of two or more components without hyperinsulinaemia, 
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the prevalence was 35.3% for men and 29.9% for women; by the presence of three or 
more components without hyperinsulinaemia, it was 12.4% for men and 10.7 % for 
women.  
One third of middle-aged Americans were in 2004 found to have the metabolic 
syndrome as defined by the national Cholesterol Education Program (NCEP) (12)  
Using NCEP criteria, the metabolic syndrome is detected in about 40% of the US 
population over 50 years. The diagnosis is most frequently driven by elevated blood 
pressure, followed by abdominal obesity and elevated fasting triglycerides (5).  
According to census data from 2000, approximately 47 million Americans meet the 
diagnosis for metabolic syndrome, corresponding to about 40% of the adult 
population. This correlates with the 61% increase in the incidence of obesity between 
1991 and 2000. It is worrisome that the increase in prevalence of the metabolic 
syndrome is higher in women than in men. In the NHANES III and NHANES 1999–
2000 studies there was a statistically significant age adjusted increase in the 
prevalence of the metabolic syndrome in women, but not in men. Young women (20–
39 years) had a 76% relative increase of prevalence, compared to a non significant 
increase of 5% in men in this age class (13). This is mainly driven by the constant rise 
in obesity in women, with presently 2 million more women than men being affected in 
the United States. 
Prevalence of metabolic syndrome in Norway, Sweden and Finland  
Little data exist on the prevalence of metabolic syndrome in Norway and the Nordic 
countries. 
Hildrum et al. (14) performed a cross-sectional analysis of >10000 participants (aged 
20-89 years of age) in a county of Northern Norway (HUNT 2) and found the 
prevalence of metabolic syndrome to be 29.6 % using the IDF definition and a 
prevalence of 25.9 % using the NCEP definition, and the prevalence increased 
strongly with age in both sexes. The most commonly fulfilled criteria were central 
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obesity (56.7% and 75% in men and women aged > 60 years, respectively) and 
hypertension (89.3% and 90.9%, respectively). 
Metabolic syndrome and risk of cardiovascular disease 
The metabolic syndrome is widely accepted as a risk factor for future type 2 diabetes 
and cardiovascular disease (15). It has been estimated that people with the metabolic 
syndrome are at approximately twice the risk of developing cardiovascular disease 
compared with those without the syndrome, and experience a five-fold increased risk 
of type 2 diabetes (16). 
Gause-Nilsson I et al. (17) measured the prevalence of metabolic syndrome, as well as 
its individual components, in an elderly Swedish cohort (n=508), using the ATP III 
definition. 22.6% were found to have metabolic syndrome. The prevalence was higher 
in men (26.3%) than in women (19.2%). One third of the total sample had at least one 
of the five risk factors for metabolic syndrome. High blood pressure (> or =130/85 
mmHg or use of antihypertensive/diuretic medication) was the most prevalent risk 
factor in both men (68.3%) and women (50.2%), while abdominal obesity was the 
overall second most common risk factor (27.2% of men and 42.7% of women).  
Another Swedish study, by Welin L et al.in 2008 (18), found the prevalence of 
metabolic syndrome in middle-aged men and women to vary from 10 to 15.8% among 
the women, from 16.1 to 26% among 50-year-old men, and from 19.9 to 35% among 
the 60-year-old men. The prevalence of the metabolic syndrome varied with the 
definition used. 
In a further study of middle-aged Swedes, the prevalence of metabolic syndrome 
defined by the ATP III definition was 14.8% among men and 15.3% among women, 
with an increase by age among women only (from 10% to 25%). Overweight was here 
also a dominant characteristic, defined by increased waist circumference (10). 
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Obesity is reported as the main cause of the rising prevalence of metabolic syndrome 
(5), and it could therefore be assumed that the prevalence of metabolic syndrome 
would also increase. Few studies have, however, explored this question. 
Ilanne-Parikka P et al. (19) investigated in 2004 the prevalence of the metabolic 
syndrome by the modified WHO definition in a cross-sectional, population-based 
sample of 2,049 middle-aged individuals (aged 45-64 years) (FINRISK) and in 522 
participants of the Finnish Diabetes Prevention Study (DPS). Metabolic syndrome 
was extremely common; 38.8% of the men and 22.2% of the women were diagnosed. 
Among women, the prevalence of the metabolic syndrome increased with increasing 
age. The high prevalence in men was mostly due to their high waist-to-hip ratio. The 
prevalence increased in both sexes with deterioration in glucose regulation. 
2.2.3 Aetiology and pathophysiology of the metabolic syndrome 
The causes of the metabolic syndrome are complex and have only been partially 
elucidated (3). The prevalence increases worldwide in accordance with the global 
increase in prevalence of obesity and diabetes (20).  
The characteristics traits of many patients are overweight/ obesity and a degree of 
insulin resistance, as well as older age (20). Although insulin resistance is not present 
in all patients (present in approx. 60-70 %), the most accepted hypothesis of the 
aetiology of the metabolic syndrome is insulin resistance (21), and abdominal obesity. 
Insulin resistance increases with increasing body fat mass. Insulin resistance, and its 
accomplice, hyperinsulinaemia, directly cause other metabolic risk factors. It is 
difficult to dissociate obesity and insulin resistance in patients with metabolic 
syndrome (1), by some, insulin resistance is considered to be at the core of the 
syndrome, while central obesity is its most prevalent clinical manifestation (3) 
Abdominal obesity and insulin resistance 
Overweight, characterised by an increased body mass index (BMI) is considered a 
risk factor for development of cardiovascular disease. However, central/ abdominal 
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obesity is more strongly associated with increased risk of insulin resistance, than BMI 
per se, and thus associated with an increased risk of cardiovascular disease and 
diabetes. However, it is not known whether visceral fat causes insulin resistance or is 
simply associated with insulin resistance (21). 
Abdominal obesity is defined as waist circumference or waist-to-hip ratio (22), and 
another particularly important anthropometric parameter has been increasingly 
applied in recent years is sagittal abdominal diameter (SAD) (22). 
Insulin resistance is commonly used as the term for a state in which there is a defect 
in the response to the action of insulin (20). The consequence is an inability to 
maintain normal glucose homeostasis. Initially, the insulin-sensitive tissues (skeletal 
muscle, fat and liver) use insulin insufficiently. The pancreas then responds by 
secreting more insulin in an attempt to maintain normal blood glucose levels, and 
hyperinsulinaemia occurs. With this increase in plasma insulin levels, normal glucose 
levels are maintained. Eventually, however, insulin secretion declines resulting in 
both elevated blood glucose and insulin levels (21).   
In obese individuals with excess intra-abdominal adipose tissue there is a tendency for 
increased concentration of non-esterified fatty acids (NEFA) in plasma.  
Lipolysis of adipose tissue triglycerides is the major source of these NEFA. Insulin 
inhibits lipolysis and is therefore a major regulator of this process (21,23). The 
enzyme responsible for catalysing lipolysis is the cyclic AMP-dependent enzyme 
hormone sensitive lipase (HSL). A fall in insulin concentration stimulates activation 
of HSL, with resulting NEFA release in plasma.  
NEFA are also derived through the lipolysis of triglyceride-rich lipoproteins in tissues 
by the action of lipoprotein lipase, another enzyme which is stimulated by insulin. 
Insulin resistance leads to less effective suppression of NEFA after meals and thus an 
increase in NEFA release into the bloodstream (21). 
 21 
These NEFA are transported directly into the portal vein and thus to the liver (21). 
The flux to the liver may have direct metabolic effects, as the liver is overloaded with 
lipids which further enhance insulin resistance (1,23).  
Increased NEFA in plasma can also impair the ability of insulin to stimulate muscle 
glucose utilisation by the glucose-fatty acid cycle (23) and suppress hepatic glucose 
production (21).  
NEFA derived from lipolysis of visceral fat are also delivered to skeletal muscle but it 
is unlikely that this is responsible for insulin resistance in skeletal muscle (21). 
Dyslipidaemia 
The MS is also associated with dyslipidaemia. There is usually an inverse relationship 
between plasma triglycerides (TG) and HDL-cholesterol concentrations, and an 
additional third component, the dyslipidaemia is therefore often characterised as the 
“lipid triad” – including high levels of TG, low levels of high density lipoprotein 
cholesterol (HDL) (21) and the appearance of small, dense low density lipoprotein 
particles (sdLDL) (24,25). Excessive postprandial lipaemia is also a common feature 
(24,25).  
The dyslipidaemia is often associated with abdominal obesity (26), and the 
pathogenesis is linked to insulin resistance and the excess flux of NEFA in plasma 
and increased uptake by the liver (3,21)  
Normally, insulin stimulates enzymes required for TG synthesis and reduces very 
low-density lipoprotein (VLDL) triglyceride and apolipoprotein B production and 
secretion (27). 
However, in MS, the excess flux of NEFA to the liver may impair hepatic insulin 
action. This leads to increased triglyceride synthesis and storage, and excess secretion 
of triglycerides as VLDL in plasma (3,25,27). 
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High plasma concentrations of these triglyceride-rich VLDL particles stimulate 
cholesterol ester transfer protein (CETP), which promotes the transfer of TG from 
VLDL to HDL and a subsequent increased catabolism of HDL and thus decreased 
HDL concentrations (3,25). In addition, TG in HDL is a substrate for hepatic lipase 
that converts HDL to smaller, denser particles which have reduced antioxidant 
capacity (25). 
The third component of the “lipid triad” associated with the metabolic syndrome is 
small dense  LDL particles (sdLDL). The formation of these sdLDL is also closely 
associated with insulin resistance and hypertriglyceridemia (27), and the VLDL-
triglyceride level is the major predictor of LDL size. The mechanism that leads to the 
formation of sdLDL is well elaborated. CETP facilitates the transfer of TG from 
VLDL to LDL in exchange for LDL cholesterol ester; hepatic lipase stimulates 
hydrolysis of the resulting triglyceride-rich LDL; and the increased lipolysis of 
triglyceride-rich LDL results in the formation of sdLDL (3,27). Thus, it seems that the 
presence of large triglyceride rich VLDL  particles is a prerequisite for sdLDL 
formation, and such correlations have been observed, although sdLDL particle do 
occur in patients with only slightly raised or normal TG levels. 
Hypertension 
Hypertension affects as much as 85% of patients with the metabolic syndrome (2), 
and is often a consequence of obesity. 
The sympathetic nervous system and renin-angiotensinaldosterone system (RAAS) is 
activated by insulin resistance and hyperinsulinaemia and this explains its relation to 
the MS (20).  
Increased visceral fat accumulation is a strong predictor of arterial hypertension as a it 
leads to overactivation of the sympathetic nervous system overactivation (3,20). 
 An increase in the sympathetic nervous system leads to sodium retention and volume 
expansion, endothelial dysfunction and alteration in renal function (2) 
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The local RAAS in the visceral adipose tissue exerts more powerful systemic effects 
compared with the subcutaneous adipose tissue (2). Activation of RAAS generates the 
production of angiotensin II and its pro-atherogenic effects, by inhibiting the 
vasodilatatory effects of insulin on blood vessels and glucose uptake into the skeletal 
muscle cells. There is a subsequent decrease in nitric oxide (NO) production in 
endothelial cells and vasoconstriction in smooth muscle cells, and inhibition of 
glucose transport (GLUT 4) in skeletal muscles (2). Insulin resistance also results in 
overactivity of angiotensin 1 receptor, which further leads to vasoconstriction and 
volume expansion.  
It has also been suggested that chronic increases in portal venous fatty acid levels may 
be responsible for hypertension that accompanies visceral obesity, by mediating 
relative vasoconstriction (2,20). 
Inflammation, endothelial function and oxidative stress  
Inflammation, endothelial function and oxidative stress 
Chronic inflammation, procoagulation and impaired fibrinolysis are features of the 
metabolic syndrome, but is not included in the clinical definition of the syndrome 
(28). Chronic inflammation in metabolic syndrome is not accompanied by infection or 
signs of autoimmunity and no massive tissue injury seem to have taken place. The 
inflammatory activation in metabolic syndrome is therefore often referred to as “low-
grade” chronic inflammation (29). 
It is now widely accepted that adipose tissue excerts other roles than soley storage and 
release of NEFA. Adipose tissue secrete a number of adipokines or adipocytokines, 
which all affect insulin action (including leptin, adiponectin, TNF-α, IL-6 and CRP) 
(28), and adipose tissue in obese individuals secrete more of these molecules than 
adipose tissue in lean individuals. The inflammatory markers that have been linked to 
the metabolic syndrome include, C-reactive protein (CRP), tumour necrosis factor 
alpha (TNF-α), fibrinogen and interleukin-6 (IL-6). 
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In addition to these inflammatory markers, adipose tissue also secretes procoagulant 
proteins such as plasminogen activator inhibitor type-1 (PAI-1), tissue factor and 
factor VII (28). 
The pathophysiology of inflammation in metabolic syndrome is not fully elucidated as 
yet. One theory is that the release of cytokines by the adipose tissue stimulates CRP 
production in the liver. Macrophage infiltration into adipose tissue in obese 
individuals can also explain the presence of increased levels of the inflammatory 
markers. Insulin resistance may also be causal of the higher cytokine production(28). 
C-reactive protein  
Chronically elevated levels of CRP are associated nearly all the main cardiovascular 
risk factors, including insulin resistance and diabetes, metabolic syndrome, 
hypertension, smoking, and dyslipidemia. A linear relationship between circulating 
levels of CRP and CVD risk has been demonstrated, and elevated CRP levels in obese 
individuals increase the risk of progression to type 2 diabetes mellitus (30).  
However, whether CRP contributes to atherosclerosis or is a marker of risk is not 
known (28).  
Elevated CRP levels associated with obesity, especially in subjects with abdominal 
obesity (31), and weight loss leads to a significant decrease in CRP levels. This 
results in a subsequent improvement in insulin resistance and thus demonstrates that 
there is a link between CRP levels and obesity (28,30). 
Increased levels of CRP have been shown to cause induction of endothelial adhesion 
proteins VCAM-1, E-selectin, and angiotensin type 1 receptor. In addition, CRP 
activates induction of endothelial PAI-1, IL-6, TNF-α, and is thus associated with 
endothelial dysfunction (28,30). 
Tumor necrosis factor-α 
The secretion of TNF-α is increased in obese individuals. It is produced primarily 
from macrophages in obese adipose tissue (30). It has been suggested that this 
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cytokine mediates insulin resistance as it blocks the action of insulin (28). Weight loss 
decrease TNF-α and insulin resistance improves with TNF-α deficiency. 
Results from animal studies suggest to the metabolic syndrome as TNF-α also seem to 
regulate plasma TG levels and glucose homeostasis in mice with targeted disruption 
of the TNF-α gene (28). 
Circulating TNF-α may also contribute by its induction of CRP production and 
general systemic inflammation. In vitro experiments have also shown that TNF-α 
induces vascular adhesion molecules and cytokines, resulting in inflammatory and 
foam cell accumulation (30). 
Interleukin-6 
IL-6 is produced by a wide rage of cells, and as much as 30% is produced in adipose 
tissue. Elevated levels of IL-6 are positively correlated with obesity, insulin resistance 
and hypertension. Visceral adipose tissue has been shown to produce larger amounts 
of IL-6 than subcutaneous adipose tissue. Obese men typically have higher waist-to-
hip ratios compared to women and may as a result experience greater metabolic 
effects from this pattern of adipose tissue deposition. This difference in fat 
distribution in men and women is emphasized in studies that have shown that in 
women with android obesity there is a similar relationship between elevated IL-6 and 
insulin resistance. 
There is growing evidence that it also has roles in inducing lipolysis and decreasing 
appetite and weight gain (30). 
IL-6 is a marker of increased cardiovascular disease, and has a role in hypertension by 
stimulating the central nervous system and the sympathetic nervous system (28).  
IL-6 production induces CRP secretion, and there are data that suggest IL-6 decreases 
lipoprotein lipase activity, which results in increased macrophage uptake of lipids. 
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Adiponectin  
Adiponectin is a plasma protein produced exclusively by adipose tissue (32). 
Physiologically, women seem to have higher adiponectin concentrations than men 
(33). Studies link hypoadiponectinaemia to the pathogenesis of obesity-related 
metabolic and vascular diseases. There is a significant negative correlation between 
BMI and plasma adiponectin levels in both men and women, and levels are negatively 
correlated with percent body fat, waist-to-hip ratio, and abdominal fat. Furthermore, 
adiponectin levels increase following weight loss. Low plasma levels are also 
associated with insulin resistance (22).  
Adiponectin enhances energy consumption and fatty acid oxidation in the liver and 
muscle (Eckel et al 2005), which reduces the tissue triglyceride content, and 
consequently improves insulin sensitivity (22). 
Adiponectin inhibits oxidative stress and inflammation (22), and is inversely 
associated with elevations in inflammatory markers. Low levels of adiponectin in 
obese women are associated with higher levels of CRP and IL-6 (28). 
Adiponectin is a highly sensitive marker for the prediction of future cardiovascular 
events, and low levels are associated with progression of coronary artery calcification 
(Sutherland 2004). Adiponectin directly improves endothelial dysfunction by 
downregulating the expression of adhesion molecules on the endothelial cells (22). 
E-selectin 
E-selectin is suggested to be a marker of atherosclerotic activity associated with the 
metabolic syndrome (34). Some investigators have reported that levels of E-selectin 
correlate to total body fat and BMI but not to fat distribution in type 2 diabetes, and 
this seems to apply to subjects with the metabolic syndrome as well (34). 
E-selectin levels may be regulated by adipocytokines such as TNF-a [12] or 
adiponectin (34). 
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Plasminogen activator inhibitor-1  
The metabolic syndrome may also be related to the elevated levels of hemostatic 
factors like fibrinogen and PAI-1. PAI-1, an inhibitor of plasminogen activation 
which stabilizes fibrin, is disordered in obesity. High levels of PAI-1 have been 
associated with MI and CHD.  
PAI-1 is synthesised and secreted by endothelial cells, mononuclear cells, 
hepatocytes, adipocytes and fibroblasts. It is regulated by the cytokines TNF-α and 
IL-6, among others.  
PAI-1 is elevated in metabolic syndrome. Elevated PAI-1 levels have been shown to 
be associated with abdominal obesity and with BMI in men and women. PAI-1 
appears to be related to the degree of obesity. For example, although insulin resistant, 
lean type 2 diabetics have been shown to have similar plasma PAI-1 levels compared 
to lean non-diabetic subjects (28). It is also correlated with other measures of obesity, 
including waist-to-hip ratio, reflecting abdominal fat, and with several metabolic 
factors, such as serum TG and insulin levels.  
There is evidence suggesting that weight loss leads to a significant reduction in PAI-1 
levels in obese subjects, due to decrease in blood lipids or insulin or reduced body 
weight. It has been shown that during weight reduction, the decrease in PAI-1 is more 
closely related to changes in adipose tissue mass than to changes in metabolic 
variables such as TG and insulin levels (28). 
PAI-1 is a regulatory protein of the coagulation cascade, which is elevated in 
inflammatory and obese states as well as in the metabolic syndrome.  
Obesity is also associated with increased circulating levels of the procoagulant factors 
tissue factor, fibrinogen, von Willebrand factor, and factor VII. Many of the 
circulating cytokines elevated in obese states also cause endothelial activation, 
resulting in low levels of platelet activation, prostaglandin secretion, and plug 
formation, and hypercoagulable state, which is thought to contribute to atherogenesis. 
This hypothesis has been validated by the demonstration that elevated levels of each 
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of these prothrombotic serum factors are associated with increased cardiovascular 
risks (30). 
Leptin 
Leptin is involved in the control of energy homeostasis and appetite regulator, and is 
one of the key vasoactive substances produced by adipocytes. During fasting, when 
plasma leptin levels decline, neural pathways in the hypothalamus cause the appetite 
to increase and energy expenditure to decrease as the body attempts to restore its fat 
stores (22). Leptin levels correlate with the amount of body fat; therefore, obese 
individuals have the highest levels of leptin, suggesting that these individuals leptin 
resistant as opposed to suffering from leptin deficiency. Leptin levels are 
physiologically higher in women than in men (33).  
The potential effects of leptin in the pathophysiology of cardiovascular complications 
of obesity remain diverse. However, leptin is thought to contribute to insulin 
resistance and is considered to be one of the links between obesity, insulin resistance, 
and atherosclerosis. (22,30). There is a positive correlation between leptin and CRP 
and other inflammatory markers in healthy and obese subjects. 
Evidence has suggested that leptin stimulates cholesterol uptake by macrophages, 
particularly in the presence of high glucose. This then triggers the formation of foam 
cells and the development of atheromatic lesions. Leptin may elevate the blood 
pressure by stimulating the autonomic nervous system. Obesity-related 
hypoadiponectinemia might also contribute to impaired endothelial function and 
overall proatherogenic effects (30).  
It remains highly likely that all these markers of inflammation, endothelial function 
and oxidative stress are associated with the pathophysiology of the metabolic 
syndrome and may therefore be a potential target of prevention and treatment (30). 
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2.3 Metabolic syndrome and dairy products  
2.3.1 Cardiovascular Disease 
Cardiovascular disease (CVD), although decreasing in prevalence in the last decades, 
is still the major cause of death in Norway. The most important risk factors for 
developing cardiovascular disease include dyslipidaemia, overweight, hypertension, 
diabetes, smoking and inactivity, all of which are related to, and highly influenced by, 
lifestyle and diet. Although still prominent, the prevalence of these major risk factors 
such as hypertension, dyslipidaemia and smoking has also decreased in the past 25 
years (35). In Norway there has simultaneously been a reduction in the intake of 
saturated fat in the (www.shdir.no). However, in this same time period the prevalence 
of obesity and diabetes has risen dramatically worldwide, Norway included. The 
reasons for this development is multifactorial (35), however, there is a clear link 
between the development of obesity and an increasingly sedentary lifestyle and an 
increase in calorie consumption (mainly due to an increase in simple carbohydrates).  
2.3.2 Metabolic syndrome and dietary recommendations 
The Metabolic Syndrome is as outlined earlier a clustering of the risk factors for CVD 
and thus diet is of major importance. There is to date, however, no consensus 
regarding specific nutrient recommendations for this syndrome. However, there is an 
agreement that energy restriction, regardless of dietary macronutrient composition, is 
beneficial for weight reduction, which consequently leads to an improvement in the 
metabolic risk factors (36). General national dietary recommendations in large parts 
of the world suggest lowering the total intake of fat; specifically saturated fat and 
trans fat intake as a means to improve the overall health of the population and to 
prevent cardiovascular disease. The same dietary principles apply for secondary 
prevention of CVD (5), in addition to specific recommendations for dietary 
cholesterol intake.    
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These general recommendations have been based on the assumption that saturated fat 
intake is associated with risk of accelerated development of cardiovascular disease 
and premature mortality from heart attack and stroke (37).   
2.3.3 Dairy food consumption in Norway 
Norway has always had a relatively high intake of milk and other dairy products.  As 
much as 75 % of the Norwegian population is milk consumers, and of the remaining 
25 % who does not drink milk, all are most likely consumers of other dairy products, 
such as either cheese or yoghurt. The intake of milk has decreased in the last 30 years, 
while yoghurt and cheese consumption has been on the increase over the past years. 
Data from 2008 and 2009 also show a slight decline in the consumption of cheese. 
Consumer data from 2009 reveals that the intake of milk was 97,3 litres per person, 
cheese and yoghurt intake per person was 17,3 kilos and 9,7 litres, respectively. 
About 82% of the total milk consumed in Norway, consists of low-fat products (0.1-
1.5 % fat). The neighbouring countries Sweden and Finland both have higher total 
intakes of milk, cheese and yoghurt compared to Norway (www.melk.no).   
Norwegians have a positive attitude towards dairy products; as surveys have shown 
that 8 out of 10 consider milk as a healthy food product. Six out of 10 are positive to 
milk drinking, men being significantly more positive than women (www.melk.no).  
Dairy products provides approximately 70% of the total daily dietary calcium intake 
in Norway, but as the overall consumption of dairy has decreased the calcium intake 
now only corresponds to 61% of the amount consumed in 1980 (www.melk.no).  
2.3.4 Dairy products and cardiovascular disease  
Milk fat is a major source of saturated fatty acids (38). Strong associations between 
intake of dairy fat and coronary heart disease have been indicated in ecologic studies 
(39-41), whereas prospective cohort studies have shown a more mixed picture 
(reviewed in (42).  
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Some studies have documented a positive correlation between the intake of dairy 
products and CHD mortality (43,44) and shown that high-fat dairy products compared 
with low-fat dairy products are associated with an increased risk of CHD (45). Other 
studies are inconclusive and do not support a correlation between the intake of dairy 
products and CHD mortality (46-50).  
Elwood et al published a review article in 2004 (51), reviewing 10 prospective cohort 
studies and 2 case-control studies on dairy products and CHD. All but one study in 
this review suggested a reduced risk of ischemic heart disease and ischemic stroke in 
subjects with the highest intake of dairy products. This review mainly looked at full-
fat dairy products as they were the most commonly used products at the time when the 
studies were undertaken.  
Moss and Freed (52) observed that consumption of whole milk was significantly 
correlated with CHD in 15 European countries. There was, however, a slightly 
negative correlation between CHD and cheese and fermented milk products. The 
result of this observational study is though limited due to only describing food 
consumption using food balance sheets.  
2.3.5 Dairy products and metabolic syndrome 
Dairy products are an important part of the Western diet as a source of good-quality 
protein and several vitamins and minerals. They may have positive as well as negative 
health effects (38,53). Some epidemiologic studies have suggested an inverse relation 
between intake of dairy products and components and prevalence of the metabolic 
syndrome (54-56), which has not been apparent in other studies (57).  
Some of the positive effects of dairy products are related to the metabolic syndrome 
and its different components. These positive findings are most certainly ascribed to 
various dairy products and its different constituents. Dairy products contain many 
different nutrients which may have various effects and characteristics that 
counterbalance the commonly expected negative effects. 
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The consumption of dairy products has been inversely associated with the prevalence 
and incidence of the metabolic syndrome in a number of epidemiological studies 
(54,55,58,59).  
The cross-sectional study by Mennen et al (59) showed that consumption of dairy 
products were inversely related with the prevalence of the metabolic syndrome in 
men, but not in women. Men who consumed more than 1 portion of dairy/ day had a 
40% lower prevalence of the metabolic syndrome compared with men who did not 
consume dairy products at all. Furthermore, Azadbakht et al (54)demonstrated an 
inverse association between dairy product consumption and the metabolic syndrome 
in Tehranian subjects aged 18-74 years. The subjects in the highest quartile of dairy 
consumption (≥3.1 servings/day of milk, yoghurt, cheese) had lower odds of having 
the metabolic syndrome compared with subjects in the lowest quartile of dairy 
consumption (<1.7 servings/ day). In addition, Elwood et al. (58) have, in the 
Caerphilly study, found a negative relationship between milk and dairy product intake 
and the prevalence of metabolic syndrome in a study among adult men.  
The Coronary Artery Risk Development In Young Adults (CARDIA) study, found an 
inverse association between the frequency of dairy intake and 10 year incidence of the 
development of metabolic syndrome, among more than 3000 young overweight men 
and women (55).  
However, which of the components in dairy products that may be responsible for 
these positive effects is not clear, neither are the mechanisms behind these effects. 
However, several intervention studies have been performed on the effects of single 
nutrients from dairy products on the different features of the metabolic syndrome. In 
this respect, much attention has been paid to calcium, protein and fat (60). 
BODY COMPOSITION  
The consumption of dairy foods and calcium in dairy foods has been suggested to be 
beneficial in the regulation of body weight (61-63), especially in observational studies 
(64). Results from intervention studies, on the other hand, are inconsistent (61,65).  
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It has also been indicated that milk consumption and intake of dairy proteins are 
inversely related to the risk of hypertension (66-68), and intervention studies have 
shown a blood pressure–lowering effect of milk products and milk peptides (56,69).  
An intervention study has shown that weight loss with milk supplementation induced 
a smaller increase in desire to eat and hunger compared to the control group. The 
effect in this study suggests that milk supplementation, du e to the protein content of 
milk, attenuates the orexigenic effect of body weight loss (70). 
A further randomized intervention study by Zemel et al (71) found that subjects on a 
weight maintenance diet who had a daily intake of ≥ 3 portions of dairy products 
exhibited greater fat oxidation and was able to consume greater energy without 
greater weight gain compared to the low dairy group (<1 portion of dairy/day).  
BLOOD PRESSURE 
The Dietary Approaches to Stop Hypertension (DASH) trial in 133 hypertensive 
American men and women (72) showed that an 8-week diet including low fat dairy 
products decreased blood pressure more than a diet high in fruit and vegetables  
Alonso et al (73) evaluated a prospective cohort study, and found that higher low-fat 
milk intake (≥3 portions/ day versus <1 portion/day) was associated with lower 
increases in systolic blood pressure in non-hypertensive whites men and women, but 
not in African Americans. 
A study by Engberink et al. (74) on elderly Dutch subjects (> 55 years of age) in the 
Rotterdam study observed that low-fat dairy intake may contribute to prevention of 
hypertension in older age (20 % risk reduction after 6 years). The subjects were non-
hypertensive at baseline and blood pressure was assessed again after 2 and 6 years.  
Wang et al (75) also confirm the observation that an intake of low-fat dairy products 
is inversely associated with risk of hypertension in middle-aged and older women (> 
45 years of age). In this prospective cohort of 28,886 US women aged >or=45 years, 
subjects with hypertension (n=8710) were identified from annual follow-up 
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questionnaires during 10 years of follow-up and intake of dairy products at baseline 
were assessed from semi-quantitative food frequency questionnaires. The risk of 
hypertension decreased in the higher quintiles of dietary calcium. Adjustments for 
dietary calcium significantly attenuated the inverse association of low-fat dairy intake 
with risk of hypertension. 
In a prospective cohort of 28,886 US women aged  45 years followed over a period of  
10 years, a high intake of low fat dairy products (top vs. lowest quintile) was 
associated with a significant 11% reduction in the risk of developing hypertension 
(76). Interestingly, this reduction in risk was also significant across quintiles of 
dietary calcium and dietary vitamin D, but was not across quintiles of calcium or 
vitamin D supplements. 
INFLAMMATION 
However, the relationship between dairy consumption and the chronic inflammation 
linked to the metabolic syndrome has not yet been studied in depth (77).  
Zemel et al (78) evaluated the acute effects of a dairy-rich diet on oxidative and 
inflammatory stress in overweight and obese subjects in a small cross-over study.   
A dairy-supplemented diet was compared with soy-supplemented eucaloric diets. The 
dairy-supplemented diet resulted in significant suppression of oxidative stress (8-
isoprostane-F (2alpha) and lower inflammatory markers (tumor necrosis factor-alpha) 
and increased adiponectin, whereas the soy exerted no significant effect.  
Van Meijl et al (79) investigated the effects of low-fat dairy consumption on 
inflammatory markers and adhesion molecules in overweight and obese subjects in an 
intervention study. Results showed a non-significant decrease in TNF-α and a non-
significant increase in TNF-α receptor-1 (s-TNFR-1) after a period of low-fat dairy 
intake (500 ml low-fat milk and 150 g low-fat yogurt). There were no other effects on 
other markers of chronic inflammation and endothelial function. 
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An intervention study investigating high-dairy eucaloric diet and hypocaloric diet in 
overweight men and women has shown clinically significant reductions in plasma 
CRP (11% and 29% respectively) and increase in plasma adiponectin concentrations 
(8% and 18% respectively) (80). These data suggested that dietary calcium may 
suppress adipose tissue oxidative and inflammatory stress associated with obesity. 
They also emphasized that dairy foods may beneficially alter circulating CRP and 
adiponectin levels independently of changes in body weight. However, the extent to 
which these mechanisms per se underlie some of the apparent cardio protective 
properties of dairy foods remains to be more thoroughly demonstrated. 
2.3.6 Metabolic syndrome and effects of dairy food components 
and individual dairy foods   
The most commonly associated component of dairy food is that of dietary calcium. 
Even though the effects of dairy products may be a result of the synergy between 
individual components, each nutrient and compound has a biological function of its 
own (81). 
MILK FAT 
Milk fat is associated with increased cholesterol levels due to its high content of 
saturated fatty acids. The main cholesterol-increasing saturated fatty acids are 
palmitic acid and myristic acid (16:0 and 14:0). These fatty acids are known to down 
regulate LDL receptor formation. The medium-chain fatty acids (8:0 and 10:0) may 
affect the cholesterol in a similar way (82).  
The association between intake of saturated fatty acids and increased cholesterol 
concentrations is well documented (83,84), and saturated fatty acids have been shown 
to impair insulin sensitivity when substituted for unsaturated fatty acids (85,86).  
For this reason the general national dietary recommendations often recommend low-
fat dairy products as part of a healthy diet to reduce the intake of saturated fat. 
 36 
TRANS FAT 
Trans-fatty acids naturally occur in dairy products, with vaccenic acid (18:1 trans-11) 
being the most abundant.  It is known that the intake of trans-fatty acids is strongly 
related to the development of CVDs. It is also known that trans-fatty acids increase 
LDL-cholesterol, triglyceride concentrations, and Lp(a) and affect prostaglandin  
balance and thereby thromogenesis, all with an impact on the  development of CVD 
(42). Natural trans-fatty acids may be less atherogenic than industrially produced 
trans-fatty acids; however, this is debatable. The content of trans-fatty acids in milk 
fat is normally between 3% and 6%. The food matrix may have an impact and there 
may be a threshold level  for the effect of trans-fatty acids to be seen (36).The 
TRANSFACT study was a randomized, controlled, crossover study investigating the 
effects of industrially compared to  natural trans-fatty acids (about 5% of daily  
energy). The study showed that industrially produced trans-fatty acids resulted in 
lower plasma HDL-cholesterol concentrations in men, compared to trans-fatty acids 
from natural sources (87). 
Saturated fats 
Dairy products provide a source of dietary saturated fatty acids. Generally, saturated 
fatty acids have been reported in the literature to increase LDL-cholesterol (83), a risk 
factor for CHD (88). However, recent evidence suggests that perhaps the saturated fat 
within dairy products may not have the same health effects as other saturated fatty 
acids (89). 
Saturated fatty acids from dairy products have been demonstrated to have a neutral 
effect on cholesterol, may increase in HDL-cholesterol, or a give a more favourable 
LDL profile overall. One cross-sectional study of 291 healthy adult males found an 
association between milk fatty acid intake and a reduction in small LDL-cholesterol 
particles reported by (90). 
The saturated fatty acids in milk fat include shorter and medium chain fatty acids 
(2:0–10:0), lauric acid (12:0), myristic acid (14:0), palmitic acid (16:0), and stearic 
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acid (18:0).  Other fatty acids in milk fat are oleic acid (18:1) and linoleic acid (18:2n-
6). The longer chained fatty acids, lauric, myristic, and palmitic acids are all 
cholesterol elevating fatty acids and it is possible that myrictic acid is the most 
cholesterol elevating fatty acid. Stearic acid is, however, different from the other 
longer chained fatty acids present in dairy fat since it may have neutral effects on 
cholesterol level (83). The proportion of stearic acid in milk fat is about 11% (36). 
Total dairy fats 
In the Hoorn study, however, low-fat dairy consumption was positively related, while 
high-fat dairy consumption was inversely related to risk factors of the metabolic 
syndrome (57). Another study (91) of 62 elderly males also found an inverse 
relationship between milk fat intake and BMI, waist circumference, fasting plasma 
glucose, and LDL–HDL ratio. These paradoxical findings suggest the effect may lay 
in the food, not primarily the saturated fat component. It also demands research on the 
whole dietary composition (and lifestyle) contexts in which milk fat is consumed.   
FERMENTED PRODUCTS 
Some studies have indicated that dairy products may have hypocholesterolemic 
effects in humans, especially skim milk and various fermented dairy products (92,93). 
A possible mechanism for the moderate cholesterol-decreasing effects of fermented 
milk products is that the intestinal bacteria bind bile acids to cholesterol, resulting in 
an excretion of bile acid-cholesterol in the faeces. The colonic fermentation of 
indigestible carbohydrates and the production of short-chain fatty acids is suggested 
to affect systemic lipid metabolism as well (94).  
Some bacterial strains have the ability to produce bioactive peptides (94). ACE 
inhibitory peptides present in fermented milk products (94) are not degraded by 
enzymes in the intestine, but are absorbed directly and can inhibit ACE in the aorta, 
which may partly explain the antihypertensive effect of fermented milks (94-96).  
 38 
CHEESE 
There is evidence suggesting that different dairy products may have very different 
effects on components of the metabolic syndrome.   
Butter has a higher concentration of milk fat than any other dairy product (94). 
Several human metabolic studies have documented the hypercholesterolaemic effect 
of butter (94). 
Controlled studies have demonstrated a cholesterolaemic effect of milk comparable to 
that of butter, whereas the possible effects on other CHD risk markers have not been 
fully elucidated (94).  
Several observational studies do not indicate a non-beneficial effect of cheese with 
regard to CHD risk (37,39,94,97). 
Well-controlled human studies have demonstrated that cheese does not increase 
plasma cholesterol to the same extent, but rather has a smaller effect in raising LDL 
cholesterol in comparison to butter and even milk (98-100). Cheese intake was 
inversely related to a first myocardial infarction in a Norwegian study (101), but in a 
Costa-Rican study, higher cheese consumption was associated with increased risk of 
myocardial infarction (36). Until now, only the effects of regular hard cheese have 
been investigated, therefore the results can therefore not be extrapolated to other types 
of cheese (94). Despite this, analyses of cross-sectional data have suggested that 
cheese consumption may result in a greater risk of obesity and the metabolic 
syndrome (102). 
This difference between butter and cheese may be explained by the unique physical 
structure of cheese, in which the fat content is encapsulated within a casein structure 
(36). 
Cheese also contains a large variety of bioactive peptides including angiotension-
converting enzyme (ACE), which may have antihypertensive effects (36).  
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2.3.7 POSSIBLE MECHANISMS OF EFFECT OF DAIRY FOODS 
AND ITS COMPONENTS 
Mechanisms of calcium on lipid profile 
Calcium may affect the serum lipid profile, and two potential mechanisms have been 
proposed. Firstly, calcium may inhibit fat absorption in the intestine. Calcium 
interacts in particular with saturated fatty acids to form Ca-fatty acid soaps and the 
formation of these insoluble complexes increases faecal fat excretion (60). The 
reduced absorption of saturated fatty acids may contribute to the LDL-cholesterol-
lowering effects of calcium. Another possible mechanism is that calcium binds to bile 
acids, thus increasing its secretion, and inhibiting bile acids reabsorption into the 
enterohepatic circulation. This consequently lead to an increase in the conversion of 
cholesterol to bile acids and ultimately decreased LDL cholesterol levels (60). 
There seems to be a difference between the effects of dairy and supplemental calcium, 
however, which may be due to the difference in the chemical form (calcium 
phosphate in dairy products vs. calcium carbonate in supplements) or due to the 
synergistic action of other dairy components (60). 
Mechanism of calcium on body composition 
Calcium may also be responsible for mediating body weight and fat mass (103). It has 
been proposed that the effects of calcium on body weight are only present in 
populations with low habitual intakes, and that at calcium consumption above 800 mg 
per day, no additive beneficial effects of increasing dietary calcium will occur. It 
might also be speculated that calcium reduce body weight and fat mass only when 
part of an energy-restricted diet. However, this is not supported by the all studies.  
For the effects of calcium on body weight and body composition, the ability of 
calcium to bind to fatty acids and thereby inhibit fat absorption is proposed as one 
possible mechanism of action. Another way by which ca might affect body 
composition is by regulating intracellular calcium levels, as hypotheised by Zemel et 
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al (104). Intracellular calcium levels are regulated by parathyroid hormone and 1,25-
hydroxyvitamin D (calcitriol). High dietary Ca depresses the levels of calcitriol, 
thereby decreasing intracellular calcium. This results in a stimulation of lipolysis. 
Additionally, low intracellular Ca inhibits the expression of fatty acid synthase, which 
is a key enzyme in de novo lipogenesis (104). Therefore, calcium intake may directly 
affect the storage and breakdown of fat in adipose tissue.  
Calcium and blood pressure 
Several potential mechanisms may explain the positive effect of calcium on blood 
pressure, including reduced membrane permeability to monovalent and divalent 
cations, reduced intracellular Ca levels, decreased concentrations of calcium 
regulating hormones, reduced sympathetic nervous system activity, and altered 
metabolism of other electrolytes, for example, increased sodium excretion (60). Again 
the effect of calcium might be mediated by suppression of the hormone calcitriol. 
Suppression of this hormone could lower intracellular Ca levels in vascular smooth 
muscle cells, thereby reducing peripheral resistance and blood pressure (105). 
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3. Aims of the study 
The aim of this study is to investigate the effect of an increased intake of dairy 
products, on markers of the metabolic syndrome, in individuals with low habitual 
dairy food consumption and traits of the metabolic syndrome.  
The hypothesis is that foods containing more dairy fat (and thus a higher proportion 
of short and medium chain fatty acids, calcium and possibly other important nutrients) 
favourably affect energy balance, appetite and the metabolic profile in subjects prone 
to develop abdominal adiposity and metabolic syndrome. Some of the main endpoints 
include effects on body weight and abdominal fat (abdominal obesity), lipid profile 
and inflammatory markers. It is also if interest to investigate whether the increased 
intake of dairy products change the composition of the participants’ diet as a whole, in 
terms of food choices and nutrient content. 
There are few interventions studies that have investigated the effects of an increased 
intake of dairy products on the metabolic syndrome. However, a prospective 
American study (the Cardia Study) found that overweight adolescents who consumed 
dairy products to develop fewer metabolic abnormalities characteristic for the 
metabolic syndrome, than those who did not (55). Findings from a Norwegian study 
showed that subjects free from myocardial infarction had higher proportions of fatty 
acids derived from dairy fat in their adipose tissue than those who developed 
myocardial infarction (106). An earlier study based on a North-American population 
has shown positive effects of dairy products on risk factors for metabolic syndrome 
(107). It is now of interest to explore whether an intervention study on a Norwegian 
population can verify results from these earlier studies. 
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4. Subjects and Methods 
4.1 Subjects 
This study was conducted at the Lipid Clinic, Rikshospitalet, Oslo University 
Hospital between January 2005 and July 2007. This study is part of a Nordic 
multicentre study undertaken simultaneously in Norway, at the University of Helsinki, 
Finland and Uppsala Univerity, Sweden. Participants were recruited and followed up 
at each centre, and the results were collated, analysed together and published 
collectively in the American Journal of Clinical Nutrition in 2009. For the purpose of 
this thesis, the Norwegian part and data are presented only. 
Apparently healthy men and women aged 30-65 years were recruited through 
advertisements in local media (newspaper and tele-text), and through personal 
contacts with subjects from the patient pool at the Lipid Clinic. 
4.1.1 Inclusion criteria  
Inclusion criteria were: limited habitual intake of dairy products (≤ 2 portions/ day; 1 
portion defined as ≤ 200g milk (sum of milk, cultural milk and/or yoghurt), 40g 
cheese or 10g butter/day)). Dairy intake was evaluated using dietary questionnaire 
and/ or interview. The other main inclusion criteria was traits of the metabolic 
syndrome (i.e. the subjects had to fulfil two or more of the criteria for  metabolic 
syndrome according to National Cholesterol Education Program Expert Panel 
(NCEP): fasting plasma glucose ≥ 6.1 mmol/l, serum triglycerides ≥ 1.7 mmol/l, 
serum HDL cholesterol < 1.0 mmol/l (40 mg/dl) (men) and < 1.3 mmol/l (50 mg/dl) 
(women), blood pressure ≥130/ 85 mmHg and waist circumference >94cm (men) and 
>88cm (women).  
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4.1.2 Exclusion criteria 
Individuals were excluded if they had BMI > 36.1 kg/m2, known type 1 diabetes, or 
treated type 2 diabetes, glycated haemoglobin (HbA1c) ≥ 7.5 %, known abnormal 
thyroid hormone levels, or high thyroid stimulating hormone (TSH) level and blood 
pressure >160/100 mmHg.  
Also excluded were individuals taking lipid lowering drugs (fibrate, statin),  those 
treated with Cyclosporin A, oral anticoagulants, protease inhibitors (indinavir, 
ritonavir, saquinavir), those individuals who had made a change within the last 6 
weeks before randomisation and during the study in the medications that could 
interfere with the lipid profile (i.e., anti- hypertensive drugs, oral corticosteroids, 
thyroid hormones, retinoids, thiazidic derivative, hormone replacement therapy), 
those using drugs affecting lipid and glucose metabolism, weight reducing drugs and 
other drugs with known metabolic effects. 
Individuals treated for/against obesity and had received medical treatment within the 
last 6 weeks (Orlistat, Sibutramine) and/or surgery ( gastroplasty, bypass), and had 
body weight changes exceeding  5% of total body weight during the last three 
months before randomisation, were also excluded. 
In addition, individuals were excluded if they had any of the following conditions: 
recent myocardial infarction (within 3 months prior to randomisation), current chronic 
pancreatitis, or identified risk or known history of acute pancreatitis, hepatic 
insufficiency, (AST and/or ALT > 2 times the upper normal limit (UNL)), acute 
alcohol intoxication, alcoholism, known cholelithiasis without cholecystectomy, renal 
failure or renal dysfunction (defined by serum creatinine levels > 135 µmol/L in 
males and > 110 µmol/L in females), known gastric or peptic ulcer or intestinal 
disease within the previous 3 months of randomisation.  
Individuals with any other severe pathology such as cancer, mental illness, etc, which, 
in the opinion of the investigator, was found to possibly pose a risk to the individual 
or confound the results of the study, were all excluded.  
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Pregnant and lactating women were also excluded. 
Furthermore, individuals having received an investigational drug in the last 30 days 
before date of randomisation, those who were unable or unwilling to comply with the 
protocol and those likely to withdraw from the study before its completion, were all 
excluded. 
4.1.3 Screening 
Two-hundred and fifty individuals responded to the advertisements and volunteered 
to take part in the study. Volunteers were sent a letter of invitation to take part in the 
study with information about the study (Appendix 2), and were later contacted by 
telephone for a screening interview (Appendix 3). Sixty-six individuals were invited 
to the clinic for a screening visit and their eligibility was assessed by evaluation of 
medical history, medical examination and intake of dairy products (with a self-
administered food frequency questionnaire). Forty-four individuals were included and 
randomised (22 in the intervention/ milk group; of which 8 were male and 14 female, 
22 individuals were randomised to the control group; of which 8 were male and 14 
female). Six participants were excluded before the study ended and a further two were 
excluded after the end of the study, i.e. thirty-six (36) participants fully completed the 
study.  
4.1.4 Ethics 
Written informed consent was obtained from all participants and it complied with the 
Declaration of Helsinki. The study protocol was approved by the Regional Committee 
for Medical Research Ethics (Region South), and is reported to Norwegian Social 
Science Data Services (Appendix 4). The study was also registered at 
www.clinicaltrials.gov. 
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4.1.5 Finances 
The project is financed by funds from Norwegian Research Council, 
Opplysningskontoret for meieriprodukter (www.melk.no) and Tine BA. 
4.2 Study design 
This study was conducted between January 2005 and July 2007. It is a randomised 
parallel group intervention study, with 4 week baseline/ run-in period followed by a 6 
months intervention period. Each participant entered the study at different dates; and 
the last participants were included in December 2006.  
4.2.1 Randomisation 
The subjects were assigned to the control or intervention groups by randomisation 
(participants were randomised in the order they came to the laboratory for tests on the 
day of randomisation; odd numbers were randomised to the intervention group and 
equal numbers were allocated to the control group). Due to the nature of the 
intervention, the study was not blinded.  
4.2.2 Intervention 
The participants in the milk group were instructed to increase their intake of dairy 
foods to at least three portions of dairy products each day (Appendix 5). They were 
not instructed to exclude or include any other foods/ food groups. The dairy products 
had to be chosen from the list below.  The subjects in the control group were 
instructed to continue with their habitual diet. 
 
Milk (white or 
fermented): 
Yoghurt/cottage 
cheese:  
1 unit/portion = 100 – 
Cheese 
1 portion= 40 grams or 
Butter and butter 
spread: 
1 portion= 10 
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1 portion = 2 dl: 
Milk, fermented milk 
or milkshake 
(flavoured or not)  
 
 
Fat content: 0.5 – 2.0 
% 
 
• Semi-skimmed 1,5 
%  
• Semi-skimmed Extra 
0,7 %  
• Soured milk 1,5 %  
Flavoured milk 0,7 % 
250 mlYogurt  
(natural, flavoured or 
with fruit) 
 
 
Fat content: 1.0 – 8.0 % 
 
• Fruit yoghurt 3,2-5.4 
% 
• Low-fat yoghurt 1,5 % 
• Muesli yoghurt 3,5 % 
• Yoghurt natural 1,5 % 
• Drinking yoghurt 1,5 
% 
• Kesam 1 % and 8.0% 
• Cottage cheese 
naturell 4,3%  
• Cottage cheese with 
jam 3.3%  
 
4 slices  
Semi-hard 
cheeses(Gouda/ 
Emmental type) 
Spreadable/ soft  
cheeses 
 
Fat content: 15 – 30 % 
 
• Cheddar type 28 % 
(Norvegia, Jarlsberg, Port 
Salut)  
• Low-fat cheddar 16 % 
• Cream cheese 
• Goat´s cheese 29% 
and 16%  
• Soft cheese 25 % 
 
gram per day 
Butter and butter 
spreads: 
 
 
Fat content: 40-
82 %  
 
• Butter 82 %  
• Butter spread 
(70 % milk 
fat), both full-
fat and 
reduced-fat 
spread 
 
 
Participants were instructed to maintain their usual diet in the run-in period. All 
participants were instructed to maintain their habitual physical activity throughout the 
study. They are also instructed to continue with possible drug prescriptions as normal. 
Dietary assessment and evaluation of compliance 
For accurate estimation of their baseline dietary intake, all participants completed a 3-
day (2 week days and 1 weekend day) weighed dietary intake after the screening visit, 
prior to staring the intervention.  
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To check for compliance, the participants performed a further three 3-day weighed 
dietary intake at 2, 4 and 6 months respectively. The intermediate dietary records were 
used to reinforce the dietary advice, given for the milk group, and to strengthen 
compliance. The results of the last 3-day weighed dietary intake (at 6 months) were 
used when calculating dietary changes during the study. 
The subjects were given detailed instruction on how to perform accurate weighed 
dietary intake records during the clinic visit (Appendix 6). Each subject was provided 
with a dietary record sheets and an electronic scale measuring with the precision of 2 
g and a maximum of 2500 g. The use of household measures as substitutes for 
weighed amounts was accepted when it was impossible to weigh the food items. 
Liquid was measured in decilitres or grams. All subjects received oral and written 
instructions to continue their normal eating habits during the dietary registration. It 
was emphasized that the purpose was to record the usual food intake and that any 
temptations to change the diet in order to lose weight or simplify the recording should 
be avoided. They were asked to record the type and amount of all foods and drinks 
consumed. The subjects were instructed to record their dietary intake on three 
consecutive days, two weekdays and one weekend day. The subjects were provided 
with addressed pre-stamped envelopes for returning their completed food diaries; 
some however returned them electronically by e-mail. The dietary records were 
checked for completeness of description of foods and amounts. Subjects were asked 
about their habitual use of any multi- or single vitamin or mineral supplements, 
however, these data were not included in the dietary analysis. Daily intakes of energy 
and nutrients were computed using a food database and software system developed at 
the Institute for Nutrition Research, University of Oslo (Beregn). 
Details of dietary intervention 
Participants in the milk group had to choose at least 3 portions per day from a list of 
dairy products provided. They had to include at least 1 portion from the cheese or 
butter group daily. The other two or more portions of dairy products could be chosen 
from any of the other groups; the milk group and yoghurt group, or they could choose 
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to have all portions from cheese or butter. Additionally, participants were free to 
choose dairy products from a “luxury group”, but not on a daily basis due to its high 
calorie content (see list below). 
All participants were provided with a diary in which they were informed to record 
their daily intake of dairy products (Appendix 7). This diary was returned at the next 
clinic visit and used to check for compliance in both the milk group and the control 
group.  
The participants purchased the dairy products of their choosing from their local 
supermarket. They were encouraged to collect the shopping receipts and were 
reimbursed the amount at the end of the study.  
Luxury group 
• Ice creams (milk based) 
• Sweetened milk drinks (milkshake, cocoa etc.) 
• Dairy desserts (rice pudding, vanilla sauce, milk puddings etc.) 
• Cream, crème fraiche and sour cream 
• Sour cream porridge 
• Cheeses with high fat content > 30% (brie, camembert etc.) 
 
4.2.3 Clinical investigations 
Each subject met for five visits; a screening visit, randomisation visit (baseline), a 
visit at 2 and 4 months and a final visit at 6 months (Appendix 8). Clinical and 
laboratory tests were conducted at randomisation/ baseline and at the end of the 
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intervention at 6 months; some parameters were also tested during the intervention 
period at 2 and 4 months (Appendix 8).  
Anthropometry and body composition 
Body weight was measured to the nearest 0.1 kg with a calibrated digital scale while 
the subjects were dressed in light clothes and no shoes. Waist circumference was with 
the subject in the standing position, with measurements obtained midway between the 
lowest rib and the iliac crest at the end of gentle expiration. The average of two 
readings was recorded. Height was measured with a mobile wall-mounted 
Stadiometer to the nearest cm. BMI was calculated via standard equation (kg/m2). 
Body composition was measured by dual-energy X-ray absorptiometry (DEXA) at 
baseline and repeated at 6 months (DPX-L; Lunar Co, Madison, WI). CVs for body 
fat mass and fat-free mass were <2%. The DEXA system provides whole-body and 
regional estimates of three main components: bone mineral, bone-free fat free mass 
(FFM), and fat mass. For the purpose of this study, fat mass was of particular interest. 
The DEXA scan provided estimates of fat mass as percentage total fat mass, total 
body fat mass in kg and regional estimations such as fat mass for both trunk fat and 
abdominal fat mass.  
Blood pressure 
Blood pressure was measured with the subject seated in an upright position in a chair, 
after 5–10 minutes rest, with the arm supported at heart level. Blood pressure was 
measured with an appropriately sized cuff using a standard, calibrated mercury 
sphygmomanometer. Three readings were taken and the average value recorded. The 
same arm was used for every blood pressure measurement at each visit.  
Blood samples 
Blood samples were drawn from an antecubital vein in the morning after an overnight 
fast (≥10 hours). Routine laboratory methods were used to measure serum total 
cholesterol, HDL and LDL cholesterol, serum triglycerides, apolipoprotein (apo) A-I 
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and apo B, plasma glucose, HbA1c, insulin, and C-peptide. The CVs for these 
methods were <7%. The fatty acid composition of serum cholesteryl esters was 
evaluated by gas chromatography of fatty methyl esters (GLC 5890; Hewlett-Packard, 
Palo Alto, CA) after separation of the serum lipids by thin-layer chromatography, as 
described previously (26). Concentrations of high-sensitivity C-reactive protein and 
complement factors (C3 and C4) were measured with an automated Konelab Analyzer 
(Thermo Fisher Scientific, Vantaa, Finland). Intra- and interassay CVs for all 3 
methods were <5%. Tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were 
measured with an automated immunoassay system (Immulite 1000; Siemens, Los 
Angeles, CA). The CVs for these methods were <7%. The serum 25-hydroxyvitamin 
D concentration was analyzed by using enzyme immunoassay kits (IDS, Boldon, 
United Kingdom). Reproducibility was ensured by adhering to the Vitamin D 
External Quality Assessment Scheme. Standardized concentrations of serum 25-
hydroxyvitamin D were used in the analysis. Leptin concentrations were measured by 
using enzyme-linked immunosorbent assay kits (R&D Systems, Minneapolis, MN). 
All samples were analyzed in duplicate. The interassay and intraassay CVs were 5.3% 
and 4.6% for serum 25-hydroxyvitamin D and 3.2% and 5.4% for leptin, respectively. 
Isoprostane excretion in urine was determined as described previously (27). Vascular 
cell adhesion molecule-1 (VCAM-1), E-selectin, and adiponectin were analyzed in 
serum with commercial enzyme-linked immunosorbent assay methods (R&D 
Systems, Abingdon, United Kingdom). Citrated plasma was used for von Willebrand 
Factor (vWF) measurement by using an enzyme-linked immunosorbent assay method 
(Asserachrom Stago Diagnostica, Asnieres, France), and plasminogen activator 
inhibitor-1 (PAI-1) activity was measured by Spectrolyse PL (Biopool AB, Umeå, 
Sweden). The interassay CVs were 5.2% for VCAM-1, 5.3% for E-selectin, 9.5% for 
adiponectin, 8.0% for vWF, and 4.4% for PAI-1. The analyses concerning glucose 
metabolism and lipid metabolism were performed locally at the routine laboratory at 
the Oslo University Hospital, Rikshospitalet. Measurements of adiponectin, leptin, 
25-hydroxyvitamin D, fatty acid composition, and markers of inflammation, 
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endothelial function, and oxidative stress were analyzed at collaborating centres in 
Sweden (Uppsala) and Finland (Helsinki).  
4.2.4 Sample size and statistical analysis 
In order to detect a clinically relevant difference of ≈1.5 cm in waist circumference 
between the intervention and control groups at a significance level of P < 0.05 and a 
power of 80 % a sample size of 120 participants was necessary for the overall Nordic 
study as a whole. The Norwegian study population consisted of 36 participants and 
the data presented include all the participants who completed the study.  
Parametric tests were used for normally distributed data. Student’s t test was used to 
test compare the difference in change from baseline to 6 months between the milk and 
control groups (Independent-samples t test). Student’s t test was also used to evaluate 
the differences in change between baseline and 6 months within the groups (One-
sample t test and Paired-samples t test for deltavalue). We also tested for difference 
between baseline values between the two groups. For data that were not normally 
distributed Wilcoxon test was used. Statistical package for the Social Sciences (SPSS) 
version 17.0 and 18.0 for Windows was used for the statistical analysis.  
 52 
5. Results  
5.1 Subjects 
More than 250 subjects were initially screened either by telephone interview or an 
initial clinic visit (exact number is unknown due to incomplete recording of all 
telephone calls). Sixty-six individuals were invited to a screening visit and, 44 
subjects were included and randomized into the study (16 male and 28 female 
subjects). Only 36 of these subjects completed the study, 17 and 19 randomized into 
the milk and control groups respectively. The reasons for excluding the eight 
remaining subjects were all related to not complying with the study protocol. Three 
subjects started hypertensive treatment, and another commenced pharmaceutical 
weight reducing therapy. One subject was diagnosed with hypothyroidism, another 
subject was diagnosed with a large abdominal cyst, both of which were considered to 
interfere with the results of the study. Two subjects withdrew the consent from the 
study (one was lost to follow-up and one was unwilling to comply with the study 
protocol. Of the excluded subjects, 5 subjects belonged to the intervention group (1 
male, 4 female) and 3 (1 male, 2 female) to the control group.  
5.2 Baseline characteristics 
5.2.1 Physical characteristics 
The control and milk groups were comparable with regards to age and sex distribution 
at the start of the study. Baseline characteristics were mainly similar (Table 1), but 
some differences between men and women within the milk and control groups for 
some of the variables were observed. The women and men differed significantly in 
weight and body composition. Women in the milk group were significantly heavier 
than men (95.7 kg ± 6.1 and 80.4 ± 8.8 respectively, P =0.001). The women in the 
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milk group also had significantly higher percentage body fat than men (43.6% ± 6.3 
versus 30.7% ± 4.6, P = 0.000) at baseline. In the control group the body weight was 
similar for men and women at baseline, however, the women had significantly higher 
body fat mass than men (35.8 kg ± 6.4 versus 26.7 kg ± 6.2, P = 0.014), and the 
women also higher percentage body fat (43.3% ± 5.7 versus 29.7% ± 3.6, P = 0.000).  
Table 1: Baseline characteristics of the study population 1 
 Control Milk P-value 
Female/ male (n) 12/7 10/7 0.80 
Age (years) 55 ± 7.4 54 ± 6.9 0.71 
Total cholesterol (mmol/l) 5.5 ± 0.94 5.9 ± 1.4 0.32 
LDL cholesterol (mmol/l) 3.6 ± 0.97 3.9 ± 1.0 0.37 
HDL cholesterol (mmol/l) 1.3 ± 0.4 1.4 ± 0.4 0.48 
TG (mmol/l) 1.8 ± 1.3 2.0 ± 1.8 0.81 
Weight (kg) 88.6 ± 1.0 86.7 ± 10.8 0.59 
Waist circumference (cm) 103.0 ± 7.9 103.5 ± 7.8 0.83 
BMI (kg/m2) 29.6 ± 3.1 29.4 ± 2.7 0.83 
SBP (mmHg) 134 ± 14 130 ± 11 0.38 
DBP (mmHg) 85 ± 7 85 ± 4 0.99 
Glucose (mmol/l) 5.4 ± 0.5 5.5 ± 0.6 0.47 
No. of Metabolic syndrome 
criteria fulfilled 
2.8 ± 0.8 2.5 ± 0.7 0.31 
1 All values are given as means in grams ± SD.  
The data was analysed by t-tests.  
* Significant value (<0.05). 
 
5.2.2 Metabolic variables 
The metabolic variables were also matched for the control and milk group, with only 
some difference between sexes within the two groups. Adiponectin levels at baseline 
were higher among women in both control and milk groups (10.0 mg/l ± 6.3 versus 
5.3mg/l ± 2.4, P =0.034 for women and men in the control group, 13.1mg/l ± 6.2 
versus 5.4mg/l ± 2.4, P = 0.004 for women and men in the milk group). There was 
also a difference in the inflammatory markers C3 and C4 between men and women in 
the control group at baseline, women had significantly higher values. 
5.2.3 Energy and nutrient intake 
With regards to dietary intake, energy and nutrient intakes; there were no significant 
difference between the control and milk group at baseline. However, men in both 
groups had a higher mean energy intake at baseline, significantly so only within the 
milk group, but there were no difference between the two groups.  
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The control group had a significantly higher percentage energy intake from protein at 
baseline (18 E% vs. 16 E%, P = 0.042), and a significantly lower vitamin D intake 
(6.4 µg/day vs. 10.2 µg/day in the milk group, P = 0.034). 
There were some differences in the macronutrient intake between men and women 
within the milk group. The men had a significantly higher daily protein intake, total 
fat intake and a tendency for a higher intake of the different fatty acids, including 
saturated fat, MUFA and PUFA than women in the same group. The men in the 
control group similarly had a higher protein intake, an only a tendency for a higher 
intake of PUFA compared to women in the same group.  
The daily fat intake and the proportions of different fatty acids in the diet did not 
differ significantly for the two groups at baseline. There was significant difference 
between the sexes at baseline within the groups for; women in the control group had a 
significantly higher intake of palmitoleic acid (16:1) (3.44 ± 0.90 and 2.29 ± 1.36 for 
women and males, respectively, P = 0.04). The daily intake of milk fat (sum of fat 
from butter and butter containing spreads, milk, yoghurt, cottage cheese, cheese, 
crème and ice-cream) was about 11 g in both groups.  
5.2.4 General health of the subjects/ Degree of Metabolic 
Syndrome 
All subjects had to fulfil ≥ 2 of the criteria for the metabolic syndrome as defined by 
the NCEP. The criteria most commonly fulfilled were waist circumference (97 %; 35 
of 36 subjects) and hypertension (present in 83.3% of the subjects, 30 subjects in 
total, 14 in milk and 16 in the control group, respectively). The average number of 
criteria fulfilled at baseline was 2.8 (± 0.8) in the control group and 2.5 (± 0.7) in the 
milk group.  
At the end of the study period the figures were 2.7 (± 0.8) and 2.7 (± 1.1), in the 
control and milk groups respectively, which was not shown to be a statistically 
significant change neither within nor between the groups. 
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5.3 Changes during the intervention period 
5.3.1 Changes in dairy food intake 
The milk group significantly increased their intake of all dairy products during the 
study period, compared to the control group (Table 2). Cheese intake increased on 
average by 18 g/d in the milk group (P = 0.009), i.e. by half a portion of cheese daily. 
Butter intake also increased in the milk group (P = 0.036), but fell short of reaching 
significance level compared to the control group (P = 0.057).  
The intake of fluid milk and yoghurt increased by an average of 163 g/d (P = 0.005) 
in the milk group. There was a tendency for women in the milk group to have the 
largest increase in their intake of total milk products (fluid milk and yoghurt) (P = 
0.061). 
The control group reduced the daily intake of dairy products by nearly half a portion 
to about one and a half portion daily (of total milk, yoghurt, cheese and butter), from 
approximately 2 portions at baseline. The milk group had a similar intake at baseline, 
with an intake of dairy of approximately 2 portions per day. This increased to a mean 
intake of approximately 3 portions daily.  
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Table 2. Dietary intake in the control group and the milk group at baseline and 6 months, as calculated from 3-day food records 1     
 
              Control (n= 16-18)                                                    Milk (n=14-17)                                                        Control vs. Milk 
                                0 mo                6mo          ð6-0  P-valuea 0 mo            6 mo      ð6-0a       P-value  P-valueb 
 
Total milk 144 ± 119 131 ± 101 -13 ± 78  0.50  170 ± 169 333 ± 134 163 ± 217 0.007*  0.005* 
Fluid milk    72 ± 91   80 ± 99    9 ± 69  0.60  145 ± 152 220 ± 89   75 ± 161 0.10  0.16 
Yoghurt etc   31 ± 53   17 ± 43 -15 ± 55  0.28    11 ± 32   35 ± 56   24 ± 71 0.20  0.08 
Cheese    20 ± 26   15 ± 14   -5 ± 26  0.44    19 ± 21   36 ± 23   18 ± 20 0.003*  0.009* 
Butter      6 ± 9                   5 ± 8    -1 ± 10  0.80      7 ± 6    12 ± 10     5 ± 8  0.036*  0.057 
Other milk   17 ± 24   14 ± 25   -3 ± 34  0.76      7 ± 14   33 ± 46   25 ± 37 0.016*  0.029* 
  
Fish    81 ± 54   84 ± 67    3 ± 97  0.90    63 ± 48   72 ± 47     9 ± 63 0.57  0.83 
Red meat 132 ± 127 101 ± 87 -31 ± 128 0.32  123 ± 60   74 ± 60  -49 ± 63 0.007*  0.61 
Poultry    35 ± 48   37 ± 43    2 ± 47  0.86    22 ± 35   59 ± 106   37 ± 86 0.11  0.15 
 
White bread   63 ± 63   92 ± 71   28 ± 80 0.15    63 ± 59   80 ± 45   16 ± 67 0.34  0.64 
Wholegrain bread  72 ± 52   56 ± 79  -16 ± 109 0.55    52 ± 50   64 ± 99   12 ± 109 0.67  0.47 
Cereals    25 ± 36   32 ± 39     7 ± 45 0.54    51 ± 53   33 ± 38  -17 ± 59 0.25  0.19 
 
Fruits  173 ± 193 138 ± 168  -35 ± 94 0.13   179 ± 130 147 ± 121  -32 ± 144 0.39  0.94 
Vegetables 188 ± 123 146 ± 100  -42 ± 122 0.16   152 ± 72 100 ± 62  -52 ± 60 0.003*  0.77  
Potatoes    69 ± 42   51 ± 59  -18 ± 70 0.29     81 ±58   59 ± 70  -22 ± 56 0.14  0.86 
  
Alcoholic  
beverages   163 ± 203 278 ± 407  114 ± 326 0.16   143 ± 240 161 ± 277   19 ± 299 0.81  0.38 
Sugar & sweets   26 ± 74   38 ± 73    12 ± 75 0.51     21 ± 32   12 ± 15    -9 ± 22 0.12  0.29 
Cakes, buns,  
cookies      33 ± 31   31 ± 36     -2 ± 35 0.86     49 ± 53   44 ± 73    -5 ± 67 0.77  0.85 
Soft drinks   76 ± 217   76 ± 133      0 ± 157 1.00     36 ± 80   69 ± 131    33 ± 135 0.35  0.52 
Fruit juices 155 ± 260 132 ± 195   -24 ± 97 0.34     68 ± 87   48 ± 74   -20 ± 87 0.40  0.91 
 
 
1 All values are given as means in grams ± SD. 0 mo = baseline data, 6 mo = end of the study. δ6-0 = difference between 6 months and baseline data 
The data was analysed by t-tests.  
a p-value for change between baseline and 6 months within group 
b p-value between groups. Difference between change in control group versus change in milk group. 
* Significant value (<0.05). 
 
5.3.2 Changes in overall food choices 
With regards to the other food groups there were no significant differences in intake 
between the two groups after six months (Table 2). There was no tendency for a 
reduction in fish intake as was the case for the Nordic population as a whole. Fish 
intake increased slightly in both groups in the Norwegian population, but not 
statistically significant. Accompanying the reduction seen in fish intake in the Nordic 
population, there was an in increase in poultry intake; this was not, however, seen in 
the Norwegian study subjects. Interestingly, in this Norwegian study population a 
significant reduction in the intake of red meat was observed in the milk group (P = 
0.007). The milk group also reduced the vegetable intake after the six months 
intervention (P = 0.003), but not significantly compared to the control group. When 
analyzed combined, fruit and vegetable intake tended to decrease, but not statistically 
significant, in both the control (P = 0.054) and milk groups (P = 0.081).  
Otherwise, there were no clear differences between the two groups after the 
intervention period.  
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Some differences within the sexes were seen, e.g. with regards to fruit and vegetable 
intake combined. There was a statistically significant decrease in fruit and vegetable 
intake among the women in the control group (P = 0.043). Men in the control group 
also significantly reduced cereal intake, while the women increased their intake (P = 
0.042). 
5.3.3 Changes in energy and nutrient intake 
The energy intake did not differ significantly between the groups during the study 
(Table 3), and in contrast to the Nordic study population as a whole, no tendency for 
an increase in the mean energy intake in the milk group in comparison to the control 
group was observed in the Norwegian subjects.  
There was no statistically significant differences between the milk and control groups 
with regards to change in macronutrient intake, only a tendency for an increase in 
percentage energy from saturated fatty acids (P = 0.056) and also a non-significant 
decrease in trans fatty acids (P = 0.082) in the milk group. In comparison, in the 
Nordic study population, the increased intake of dairy products in the milk group was 
associated with a higher intake of protein, fat, and especially saturated fat.  
Furthermore, in this Norwegian study population, the percentage energy intake from 
PUFA was significantly decreased after six months (P = 0.028) and percentage energy 
intake from MUFA tended to decrease (P = 0.09). The control group on the other 
hand, showed a significant reduction in total fat (P = 0.020), a tendency for decreased 
saturated fat intake (P = 0.074), and also a significant reduction in the intake of both 
MUFA and PUFA (P = 0.040 and 0.013, respectively). However, there were no 
significant differences between the control and milk groups.  
The intervention did not influence protein intake, total carbohydrate intake or sugar 
intake, or the intake of alcohol in the Norwegian study population, which is in 
contrast to the Swedish study population. The intervention period also led to increased 
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intake of dietary cholesterol and calcium in the milk group compared to the control 
group (P= 0.044 and 0.007 respectively) (Table 3). 
Table 3. Intake of energy and nutrients in the control group and the milk group at baseline and 6 months 1     
                                           Control (n=18)                          Milk (n=16-18)                                          Control vs. Milk 
             0 mo            6 mo         ð 6-0                   P-valuea  0 mo           6 mo         ð 6-0  P-valuea P-valueb 
 
Energy (kJ)  8312 ± 2711 7543 ± 2345 -769 ± 1967 0.14  8446 ± 2808 8244 ± 2642 -202 ± 1935 0.68  0.44 
 
Protein (g)      88 ± 34     80 ± 23   -7.8 ± 27.1 0.24      79 ± 26     85 ± 32   6.4 ± 22.1 0.26  0.11 
(E%)    18.0 ± 3.1  18.6 ± 4.1 0.64 ± 4.3 0.53   16.0 ± 2.7  17.8 ± 4.0   1.7 ± 4.8  0.17  0.49 
Carbohydrates (g)                196 ± 88   184 ± 58           -11.5 ± 63.9 0.46    196 ± 60   190 ± 59  -6.3 ± 45.0 0.59  0.79 
 (E%)     40.1 ± 9.3  42.1 ± 7.6    2.0 ± 7.7 0.28   40.9 ± 9.4  40.3 ± 8.9  -0.6 ± 4.7 0.64  0.24 
    Sugar (g)       84 ± 59     72 ± 37 -12.5 ± 36.3 0.16      82 ± 40     83 ± 38   1.1 ± 31.8 0.90  0.26 
Fat, total (g)       81 ± 36     64 ± 27 -17.0 ± 28.2 0.020*      89 ± 43     84 ± 36  -5.2 ± 28.2 0.47  0.23 
      (E%)    35.6 ± 7.9  30.5 ± 6.1   -5.1 ± 9.0 0.029*   37.9 ± 7.6  36.8 ± 5.5  -1.2 ± 5.3 0.40  0.13 
   SAT (g)    27.6 ± 45.4  23.4 ± 9.1   -4.2 ± 9.3 0.074   31.3 ± 14.0  33.3 ± 12.8    2.0 ± 11.4 0.50  0.093 
     (E%)                   12.3 ± 3.6  11.4 ± 2.0   -0.9 ± 3.6 0.28   13.7 ± 3.4  15.1 ± 3.7    1.4 ± 3.4 0.11  0.056 
   MUFA (g)     28.3 ± 14.0  21.5 ± 10.9  - 6.9 ± 13.1 0.040*   31.4 ± 16.6  28.1 ± 15.6   -3.3 ± 11.7 0.27  0.41 
     (E%)                   12.4 ± 3.2   10.2 ± 3.4   -2.2 ± 4.6 0.063   13.3 ± 3.1  12.0 ± 3.0   -1.3 ± 2.8 0.09  0.52 
   PUFA (g)     16.9 ± 9.0  12.8 ± 6.2   -4.1 ± 6.2 0.013*   17.7 ± 11.6  13.7 ± 7.1   -4.0 ± 8.9 0.090  1.0 
     (E%)                     7.3 ± 2.5    6.1 ± 1.9   -1.3 ± 2.1  0.024*     7.3 ± 2.4    5.9 ± 1.7   -1.5 ± 2.4 0.028*  0.78 
   Trans (g)       0.7 ± 0.4    0.6 ± 0.2   -0.1 ± 0.4 0.24     0.9 ± 0.3    1.1 ± 0.5    0.2 ± 0.5 0.22  0.082 
     (E%)                     0.3 ± 0.2    0.3 ± 0.1 -0.03 ± 0.2 0.45     0.4 ± 0.1    0.5 ± 0.2  0.08 ± 0.2 0.14  0.098 
Alcohol (g)     11.5 ± 14.4  19.4 ± 24.1    7.9 ± 23.2 0.17   10.1 ± 17.8  10.6 ± 14.2    0.5 ± 17.5 0.91  0.31 
     (E%)                     4.2 ± 5.9    6.5 ± 7.4    2.4 ± 7.5 0.20     2.9 ± 4.5    3.2 ± 3.9    0.3 ± 3.7 0.74  0.32 
 
Cholesterol (mg)       394 ± 196   315 ± 153    -79 ± 189 0.095    317 ± 160   360 ± 203     43 ± 143 0.25  0.044* 
 
Dietary fiber (g)                  21.2 ± 6.1  20.3 ± 7.8   -0.8 ± 6.6 0.60   22.8 ± 6.8   19.4 ± 5.9   -3.4 ± 6.6 0.059  0.27 
 
Vitamin D (µg)                    6.4 ± 2.8    5.4 ± 3.9   -1.0 ± 4.8 0.39   10.2 ± 6.4   10.4 ± 11.3    0.2 ± 8.5 0.91  0.60 
 
Calcium                    570 ± 253   512 ± 247    -58 ± 163 0.15    601 ± 332    809 ± 221   208 ± 324 0.021*  0.007* 
1 All values are given as means in grams ± SD. 0 mo = baseline data, 6 mo = end of the study. δ6-0 = difference between 6 months and baseline data.  
The data was analysed by t-tests.  
a p-value for change between baseline and 6 months within group 
b p-value between groups. Difference between change in control group versus change in milk group. 
* Significant value (<0.05). 
 
5.3.4 Changes in milk fat intake 
The daily intake of milk fat (sum of fat from butter and butter containing spreads, 
milk, yoghurt, cottage cheese, cheese, cream and ice cream) was about 11 g in both 
groups at baseline. The intake increased in the milk group during the intervention, and 
the changes of milk fat intake in the two groups were highly significantly different (P 
= 0.000). The actual milk fat intake in the milk group increased to about 25 grams per 
day. 
5.3.5 Fatty acid composition of serum cholesteryl esters 
The fatty acid composition of the serum cholesteryl esters, reflecting the fatty acid 
composition of the diet, was similar during the two test periods (Table 4). The only 
exception was a highly significant increase of the proportion of pentadecanoic acid 
(15:0, P = 0.006) seen in the Milk group, and also a significant difference in myristic 
acid (14:0, P = 0.015), as it increased in the milk group. 15:0 is a specific marker for 
 59 
intake of dairy fat and the data confirms that these subjects had significantly increased 
their intake of fat from milk products.  
In spite of the increase of dairy products and milk fat in the diet, there were no other 
changes in the proportions of other saturated or monounsaturated fatty acids in serum 
and the proportions of polyunsaturated long-chain fatty acids of the n-6 and n-3 
family remained unchanged. These data are in accordance with the nutrient data, 
indicating a virtually unchanged dietary fat composition as concerns the major fatty 
acids. 
Table 4. Fatty acid composition of serum cholesteryl esters in the control group and the milk group at baseline and 6 months 1     
 Control (n =18 ) Milk (n =17 ) Control vs. Milk 
Fatty acid 0 mo 6 mo δ 6-0 P-valuea 0 mo 6 mo δ 6-0 P-valuea P-valueb 
 % of fatty acids  % of fatty acids   
      
Myristic, 14:0 0.82 ± 0.19 0.75 ± 0.20 -0.07 ± 0.12 0.027* 0.85 ± 0.25 0.97 ± 0.29 0.12 ± 0.27 0.083 0.015* 
Pentadecanoic, 15:0 0.20 ± 0.04 0.19 ± 0.04 -0.02 ± 0.03 0.045 0.20 ± 0.05 0.23 ± 0.08 0.03 ± 0.06 0.036* 0.004* 
Palmitic, 16:0 11.29 ± 0.61 11.25 ± 0.61 -0.03 ± 0.58 0.81 11.13 ± 0.87 11.32 ± 0.85 0.20 ± 0.66 0.24 0.28 
Palmitoleic, 16:1 2.93 ± 1.17   2.86 ± 1.13 -0.07 ± 0.40 0.47 3.00 ± 0.83 3.26 ± 0.81 0.26 ± 0.94 0.28 0.18 
Stearic, 18:0 0.89 ± 0.23   0.82 ± 0.17 -0.07 ± 0.11 0.017* 0.87 ± 0.15 0.94 ± 0.35 0.07 ± 0.35 0.42 0.14 
Oleic, 18:1 18.99 ± 2.08 19.30 ± 1.69 0.31 ± 1.16 0.27 19.12 ± 1.72 19.47 ± 1.99 0.35 ± 1.27 0.27 0.91 
Linoleic, 18:2n-6 51.47 ± 3.62 52.04 ± 3.88 0.57 ± 2.68 0.38 51.73 ± 4.242 51.18 ± 3.37 -0.55 ± 3.16 0.48 0.27 
γ-Linolenic, 18:3n-6 0.89 ± 0.45   0.89 ± 0.45 0.00 ± 0.33 0.97 0.92 ± 0.40 1.06 ± 0.34 0.15 ± 0.33 0.089 0.21 
α-Linolenic, 18:3n-3 0.60 ± 0.14 0.57 ± 0.15 -0.03 ± 0.14 0.34 0.53 ± 0.13 0.56 ± 0.15 0.03 ± 0.13 0.29 0.16 
Di-homo-γ-linolenic, 
20:3n-6 
0.78 ± 0.18 0.76 ± 0.17 -0.02 ± 0.08 0.28 0.79 ± 0.19 0.88 ± 0.42 0.09 ± 0.35 0.31 0.20 
Arachidonic, 20:4n-6 6.71 ± 0.94 6.82 ± 1.19 0.11 ± 0.60 0.44 6.41 ± 1.51 6.34 ± 1.54 -0.06 ± 0.54 0.63 0.37 
Eicosapentaenoic, 
20:5n-3 
3.27 ± 1.32 2.66 ± 1.48 -0.60 ± 1.03 0.024* 3.35 ± 1.94 2.72 ± 1.11 -0.62 ± 1.79 0.17 0.96 
Docosahexaenoic, 
22:6n-3 
1.16 ± 0.25 1.08 ± 0.22 -0.15 ± 0.36 0.13 1.12 ± 0.27 1.06 ± 0.25 -0.06 ± 0.25 0.36 0.93 
1 All values are given as means in grams ± SD. 0 mo = baseline data, 6 mo = end of the study. δ6-0 = difference between 6 months and baseline data 
The data was analysed by t-tests.  
a p-value for change between baseline and 6 months within group 
b p-value between groups. Difference between change in control group versus change in milk group. 
* Significant value (<0.05). 
 
5.3.6 Changes to anthropometric and clinical variables 
The Norwegian population remained unchanged with regards to body weight, BMI 
and waist circumference during the intervention (Table 5), as did body fat mass and 
the proportion of body fat. There was no significant change in blood pressure between 
the two groups, only a slight tendency for an increase in systolic blood pressure in the 
milk group (P = 0.064).Similar changes were found in the Nordic population study as 
a whole. 
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Table 5. Anthropometric variables, body composition and blood pressure in control group and the milk group at baseline and 6 months 1     
             Control (n=18-19)                                                                                  Milk (n=18-19)                                                    Control vs. Milk 
Variable   0 mo           6 mo       δ 6-0             P-valuea  0 mo            6 mo         δ 6-0                      P-valuea P-valueb 
Body Weight (kg) 88.6 ± 9.9 87.9 ± 9.8 -0.6 ± 2.2  0.25  87.1 ± 10.3 87.1 ± 11.0   -0.3 ± 2.3                0.96               0.45 
          
I (kg/m2)  29.6 ± 3.1 29.4 ± 3.1 -0.2 ± 0.7 0.23  29.6 ± 2.6 29.5 ± 2.7 -0.03 ± 0.8      0.88  0.48   
Waist (cm)             102.9 ± 7.9          100.9 ± 7.8 -2.1 ± 2.5 0.002*             103.4 ± 7.5           101.8 ± 7.5   -1.5 ± 3.8      0.09  0.62 
ody fat mass (kg) 33.8 ± 7.3 33.1 ± 7.7          -2.04 ± 5.8 0.17  32.7 ± 7.0 32.3 ± 7.1    0.3 ± 1.4      0.38               0.13  
Body fat (%)  40.3 ± 7.7 39.6 ± 7.7 -2.2 ± 6.6 0.21  39.4 ± 8.1 39.1 ± 8.1    0.3 ± 1.3      0.32               0.15  
SBP (mmHg)             133.7 ± 14.4         134.4 ± 13.7         0.74 ± 12.5 0.80             130.6 ± 11.2        133.8 ± 13.1  3.26 ± 7.2        0.064 0.45   
DBP (mmHg)  84.6 ± 6.8  83.9 ± 8.9         -0.74 ± 6.7  0.64             85.11 ± 4.1            84.2 ± 6.9 -0.95 ± 5.5      0.47  0.91 
 
1 All values are given as means in grams ± SD. 0 mo = baseline data, 6 mo = end of the study. δ6-0 = difference between 6 months and baseline data. 
 The data was analysed by t-tests.  
a p-value for change between baseline and 6 months within group 
b p-value between groups. Difference between change in control group versus change in milk group. 
* Significant value (<0.05). 
 
The changes in plasma glucose, insulin, C-peptide, or HbA1c were not significantly 
different between the milk and the control groups (Table 6). There was, however, a 
tendency to a difference in fasting insulin concentrations (P = 0.078) and a significant 
difference between changes in the homeostasis model of assessment (HOMA) index 
(P = 0.037) between the groups. The HOMA values are based on the Nordic study 
population as a whole, as the Norwegian data was not made available for separate 
analysis.  
Table 6. Glucose and glucose homeostasis variables in control group and the milk group at baseline and 6 months 1     
              Control (n=17-18)                                                                                   Milk (n=17-19)                                      Control vs. Milk 
Variable   0 mo           6 mo       δ 6-0a                P-value                 0 mo            6 mo        δ 6-0a                   P-value                P-valueb 
Glucose (mmol/l) 5.40± 0.53 5.43 ± 0.54 0.03 ± 0.48 0.78    5.48 ± 0.63   5.35 ± 0.59  -0.13 ± 0.74 0.47  0.44 
nsulin (pmol/l)             68.83 ± 32.58      94.06 ± 71.90       25.22 ± 60.14 0.09  79.67 ± 37.18 76.89 ± 39.82 -2.78 ± 25.56 0.65  0.078  
peptide (nmol/l)            1.04. ± 0.38 1.09 ± 0.46 0.48 ± 0.26 0.45    1.03 ± 0.24    1.02 ± 0.22       - 0.01 ± 0.17 0.75  0.41 
HbA1c (%)  5.46 ± 0.26 5.46 ± 0.25 0.00 ± 0.14 1.0    5.47 ± 0.35   5.56 ± 0.32   0.08 ± 0.23 0.13  0.19 
HOMA index                16.5 ± 10.3         19.6 ± 15.8            3.1 ± 12.2                                         15.5 ± 8.8            14.9 ± 8.2             -0.6 ± 6.2                                      0.00372* 
1 All values are given as means in grams ± SD. 0 mo = baseline data, 6 mo = end of the study. δ6-0 = difference between 6 months and baseline data.  
2 Values given for the Nordic study population as a whole, including Norway, but Norwegian data not available for separate analysis. 
The data was analysed by t-tests.  
a p-value for change between baseline and 6 months within group 
b p-value between groups. Difference between change in control group versus change in milk group. 
* Significant value (<0.05). 
 
There was no significant change in the lipid profile of the Norwegian subjects (Table 
7).  
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Table 7. Lipid variables in control group and the milk group at baseline and 6 months 1     
     Control (n=17-18)                                                       Milk (n=17-19)                                                              Control vs. Milk 
Variable       0 mo             6 mo        δ 6-0                   P-value a                0 mo            6 mo        δ 6-0                     P-value a             P-valueb 
Cholesterol        5.5 ± 0.95   5.5 ± 0.94 0.00 ± 0.40 1.0  5.92 ± 1.41 5.94 ± 1.46 0.02 ± 0.72 0.92  0.93 
(mmol/l) 
LDL cholesterol       3.6 ± 0.97   3.7 ± 0.77 0.11 ± 0.71 0.52  3.91 ± 1.02 4.08 ± 1.02 0.17 ± 0.81 0.40  0.80 
(mmol/l) 
HDL cholesterol     1.28 ± 0.35 1.26 ± 0.35 -0.02 ± 0.18 0.61  1.39 ± 0.40 1.34 ± 0.40 -0.05 ± 0.20  0.32  0.67 
(mmol/l) 
Triglycerides     1.84 ± 1.33 1.84 ± 1.29        -0.005 ± 0.69 0.97  2.07 ± 1.76 2.21 ± 1.92  0.13 ± 0.70  0.42  0.55 
(mmol/l) 
B (g/l)     1.08 ± 0.27 1.05 ± 0.25 -0.03 ± 0.09 0.14  1.16 ± 0.33 1.11 ± 0.34 -0.04 ± 0.17 0.28  0.78 
 A-I (g/l)     1.37 ± 0.27 1.40 ± 0.29  0.03 ± 0.13  0.40  1.39 ± 0.25 1.42 ± 0.20  0.03 ± 0.16 0.47  0.98 
1 All values are given as means in grams ± SD. 0 mo = baseline data, 6 mo = end of the study. δ6-0 = difference between 6 months and baseline data.  
The data was analysed by t-tests.  
a p-value for change between baseline and 6 months within group 
b p-value between groups. Difference between change in control group versus change in milk group. 
* Significant value (<0.05). 
 
One significant observation was seen in the change in E-selectin, a marker of 
endothelial function in the milk group. This marker significantly decreased in the 
Norwegian milk group compared to the control group. This is in contrast to the 
Nordic study population as a whole. 
Otherwise, no significant differences were observed between the groups with regards 
to the variables related to inflammatory response (leptin, IL-6, hs-CRP, TNF-α, C3, 
and C4), endothelial function (vWF), fibrinolysis (PAI-1) and oxidative stress (Table 
8). The serum concentration of 25-hydroxyvitamin D also remained unchanged.  
Table 8. Markers of inflammation, endothelial function and oxidative in control group and the milk group at baseline and 6 months 1 
  Control (n=17-18)                             Milk (n=17-19)                                            Control vs. Milk 
Variable   0 mo           6 mo       δ 6-0                   P-value  a              0 mo            6 mo        δ 6-0                    P-value a   P-value b 
Adiponectin (mg/l) 8.1 ± 5.7 8.01 ± 5.5 -0.1 ± 3.0 0.94  9.9 ± 6.3 10.4 ± 6.4 0.5 ± 2.1 0.37     0.55 
Leptin (ng/ml)           27874 ± 20649      24498 ± 1251      -3376 ± 9290          0.13                29075 ± 19819      30634 ± 18438    1559 ± 12962         0.61           0.19   
hsCRP (mg/l)              2.84 ± 2.83 2.59 ± 2.83        -0.25 ± 1.83 0.56             4.04 ± 3.21            4.57 ± 3.68        0.53 ± 1.65 0.20     0.19  
C3 (g/l)               1.30 ± 0.25 1.29 ± 0.25      -0.004 ±  0.15 0.90             1.40 ± 0.20 1.42 ± 0.20        0.02 ± 0.14 0.49     0.57 
C4 (g/l)               0.30 ± 0. 8 0.31 ± 0.09       0.004 ± 0.05 0.69             0.31 ± 0.82 0.32 ± 0.08      0.004 ± 0.04 0.64     0.99 
6 (pg/ml)              3.77 ± 5.27 4.28 ± 5.15         0.51 ± 1.30 0.11             2.96 ± 1.41 3.58 ± 1.18        0.62 ± 1.75 0.14     0.82 
TNFalpha (pg/ml)            9.88 ± 2.25          10.23 ± 3.01         0.35 ± 1.93 0.44             9.73 ± 1.93           10.12 ± 2.20       0.39 ± 1.38 0.23     0.93 
VCAM (ng/ml)               607 ± 170   580 ± 135  -27 ± 65 0.09              565 ±  109   522 ± 134         -42 ± 78  0.039     0.52  
selectin (ng/ml)            33.1 ± 12.7  34.0 ± 8.1   0.8 ± 7.5 0.64             40.4 ± 15.6  32.2 ± 9.88       -8.2 ± 11.1 0.013*     0.008* 
vWF (%)               132 ± 45                138 ± 47      6 ± 21 0.21               137 ± 48                  143 ± 44   6 ± 42  0.55     1.0 
1 (U/ml)              20.4 ± 8.8  22.0 ± 11.4   1.6 ± 40.5 0.50             21.1 ± 8.4                18.6 ± 7.6        -2.5 ± 7.2               0.17     0.18 
-PGF2alpha              0.60 ± 0.39            0.49 ± 0.25        -0.11 ± 0.32          0.19                    0.52 ± 0.29             0.47 ± 0.18     -0.05 ± 0.37            0.61            0.62 
(nmol/mmol creatinine) 
OH-D(nmol/l)           83.02 ± 29.45        89.36 ± 29.47 6.34 ± 30.55 0.38            99.38 ± 42.05       108.39 ± 29.40    9.01 ± 32.02          0.24     0.79 
1 All values are given as means in grams ± SD. 0 mo = baseline data, 6 mo = end of the study. δ6-0 = difference between 6 months and baseline data.  
The data was analysed by t-tests.  
a p-value for change between baseline and 6 months within group 
b p-value between groups. Difference between change in control group versus change in milk group. 
* Significant value (<0.05). 
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Regression analyses relating the changes in the proportions of 15:0 in serum 
cholesteryl esters (specifically mirroring the changes in intake of milk fat) with those 
of the clinical variables showed that the increase in serum cholesterol was 
significantly related to that of 15:0 (r = 0.24, P = 0.011), which suggests that the 
increased cholesterol concentrations were in fact due to the increased intake of milk 
fat. There was no significant correlation between changes in the HOMA index and 
15:0 in the serum cholesteryl esters.  
5.3.7 Effects related to habitual calcium intake 
As explained in the published scientific paper, there may be a possible threshold for 
the effect of dairy products and dietary calcium on blood pressure. This threshold has 
been suggested at a calcium intake of 700–800 mg/d (108). Among the Norwegian 
study population about 40 of the subjects in the milk group had a calcium intake at 
baseline that exceeded this limit (7 out of 17 subjects). In a post hoc analysis, the 
participants were thus divided into 2 groups with a daily calcium intake below (n = 
25) and above (n = 10) 700 mg, respectively, and the effects on body composition 
(BMI, waist circumference, SAD, body fat mass, and body fat proportion) and blood 
pressure were tested.  
Among the participants with a low calcium intake, there was a significant treatment 
effect for waist circumference (P = 0.023). In the subjects with a low calcium intake 
at baseline, waist circumference was 105.1 ± 8.6 cm at baseline and 101.5 ± 9.7 cm at 
6 months in the milk group, but remained essentially unchanged in the control group 
(103.3 ± 7.5 and 101.7 ± 7.3 cm, respectively). There were no other effects related to 
the level of calcium intake on BMI, body fat mass, or the proportion of body fat.  
Similar results were observed in the Nordic study population as a whole with regards 
to treatment effect on waist circumference, in addition, the milk group in Nordic study 
population had a significant treatment effect for diastolic but not for systolic blood 
pressure in the Nordic study population. 
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6. Discussion 
6.1 Biomarker of milk fat intake 
In this controlled 6-months dietary intervention study, dietary records and analyses of 
a serum biomarker for intake of milk fat (pentadecanoic acid, 15:0) were used to 
verify that the participants in the milk group had significantly increased their intake of 
dairy products (Table 2). The participants received no advice concerning dietary 
changes, except for the instruction to increase the intake of dairy products. On the 
contrary, the intention was to allow for adjustments of energy intake and other 
compensatory dietary changes to study the consequences of a higher intake of dairy 
foods.  
6.2 Changes in dairy intake 
The major change in dairy intake in the milk group was an increase in milk intake, 
ordinary as well as fermented, and of cheese. The subjects mainly were instructed to 
consumed low-fat dairy or moderate-fat dairy products, which probably explain the 
rather small non-significant mean increase in saturated fat. The Swedish participants, 
on the other hand, included more full-fat products, as is seen in a resultant increased 
saturated fat intake for the Nordic study population as a whole.  
6.3 Changes in energy intake 
The mean energy intake did not change significantly either during the intervention 
period. There was, in fact, a non-significant decrease in both the milk group and the 
control group. This indicates that the higher intake of dairy products in the milk group 
was balanced by a reduced intake of energy and nutrients, including saturated fatty 
acids, from other food groups. 
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In comparison, in the Nordic study population as a whole, there was a tendency for an 
increase in mean energy intake in the milk group compared to the control group (P = 
0.07) mean energy intake in the milk group tended).  
This discrepancy in results between the Norwegian and Nordic study populations may 
again be explained by the difference in methods in Sweden and Norway, with regards 
to the difference in choice of dairy products (low-fat and moderate-fat dairy products 
versus full-fat dairy products). The choice of low-fat dairy products has resulted in 
substitution for other foods items in the diet, but has subsequently not led to an 
increase in mean daily energy intake. The increased dairy intake in the Norwegian 
milk group has apparently as a consequence led to a reduction in red meat intake, and 
thereby a probable reduction in saturated fatty acids, which explains why saturated 
fatty acid intake did not increase significantly and this may also help explain why the 
mean energy intake did not increase.  
6.4 Changes in clinical variables 
6.4.1 Body composition 
Despite a significantly increased intake of milk protein and calcium, there were no 
significant changes in body weight, abdominal fat, or the proportion of body fat in the 
milk group. Thus, we found no support for earlier suggestions that a higher 
consumption of dairy products, or of calcium in dairy products, would affect body 
weight or body fat accumulation (56,61,63). The effect of calcium may, however, be 
beneficial during weight loss, and dairy products may enhance the effect of calcium 
on weight loss (107), the mechanisms remain largely unclear although there are 
several suggested mechanisms (105), including increased fecal fat excretion and 
stimulation of lipolysis and inhibition of lipogenesis (by suppression of 1,25-
dihydroxyvitamin D) (94,109). Similar to our results, an intervention during 1 y in 
young healthy women who increased their intake of dairy products and calcium did 
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not lead to alterations in body weight or fat mass (110). Also, earlier systematic 
studies have provided little support for an effect of dairy intake on body weight and 
fat loss (111,112). The long-term consequences of an increased intake of calcium or 
dairy products as a part of an ordinary and unrestricted diet on body weight or body 
fat accumulation remain unclear. Some studies imply that calcium shows its effect 
only when part of an energy-restricted diet (60), and as this Norwegian study did not 
result in reduced energy intake, the calcium effect on body weight and blood pressure 
may not have been evident.  
6.4.2 Hypertension 
Epidemiologic studies suggest that consumption of milk and milk products is 
inversely related to the risk of hypertension (66-68), possibly because of an increased 
intake of calcium and/or magnesium (113) or to the content of protein or specific 
biologically active peptides (69,114). In apparent contrast with some (115,116), but 
not all (65), earlier intervention studies, the blood pressure in the Norwegian study 
population and in the Nordic study population as a whole remained unchanged (Table 
5), despite significant increase in calcium intakes and total dairy intake. It has been 
suggested that the effect of calcium is greater in persons who already have 
hypertension (117), although a meta-analysis gave no support for this hypothesis 
(118). The majority of the Norwegian subjects (n=30, 83%) had raised blood pressure 
at baseline and 60% (n=18) received hypertensive treatment prior to starting the study 
(11 in the control group and 7 in the milk group, respectively). One could expect that 
the significant increase in calcium therefore would have a treatment effect on blood 
pressure specifically. The lack of treatment effect observed, however, may be due to 
several factors; the small sample size for instance and short intervention period. 
Furthermore, it has been suggested that there may be a possible threshold for the 
effect of dairy products and dietary calcium on blood pressure. This threshold has 
been suggested at a calcium intake of 700–800 mg/d (108). Among the Norwegian 
study population 41 % (n =7) of the subjects in the milk group had a calcium intake at 
baseline that exceeded this limit. However, no treatment effect on blood pressure was 
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seen for those who had a calcium intake lower than 700mg/day. Among the subjects 
with a low calcium intake, there was, however, a significant treatment effect for waist 
circumference (P = 0.023). No treatment effect was seen for blood pressure in the 
Norwegian milk group though, as was seen in the Nordic study population as a whole. 
Again, this may be due to a small sample size in the Norwegian study population. The 
active form of vitamin D status is important for maintaining calcium levels in the 
body. The 25-hydroxy vitamin D test is the most accurate way to measure vitamin D 
status. The result in this study shows that vitamin D status is optimal (above 
recommended level 75-105 nmol/l) for both the control and milk groups; but there 
was no significant change in either of the groups after 6 months (Table 8). 
Nevertheless, the fact that vitamin D status was optimal indicates that the increased 
calcium intake is well absorbed. 
6.4.3 Dyslipidaemia 
This study used a validated specific biomarker of dairy fat intake in humans (119-
121) to confirm an increased intake in milk fat. Despite this confirmation of increased 
intake of dairy fat, reflected in a significant increase in 15:0 in cholesteryl esters, no 
change in the lipid profile was seen in the Norwegian milk group, including LDL 
cholesterol and apo B lipoprotein.  
Contrary to this, in the Nordic study population, an increase in serum cholesterol was 
mainly seen in the Swedish cohort, which also had the largest increase in milk fat 
intake among the three countries. There was also a significant increase in serum apo 
B lipoprotein concentrations within the Swedish milk group only. 
Although not included as a criterion for the metabolic syndrome, LDL cholesterol is 
of interest in this context due to its association with increased CVD risk and as part of 
the dyslipidaemic triad. Metabolic studies show that most saturated fatty acids, with 
the exception of stearic acid and short-chain fatty acids raise LDL cholesterol 
significantly (37). However, it has been suggested that dairy fats solely raise the large 
and less atherogenic subpopulation of LDL particles (90). Simple LDL measure is 
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known not to fully predict the cardiovascular risk; small dense LDL particles are 
considered the most atherogenic. This analysis was not performed in this study, and it 
is therefore difficult to predict whether there has been a change in the size of LDL 
particles, in one way or the other. However, when calculating the aboB/apoA1 ratio in 
the Norwegian subjects, no significant change was observed. The apoB/apoA1 ratio is 
also linked to an increased risk of CVD and an elevated ratio of apoB/apoA1 (≥0.97 
for men and ≥ 0.86 for women) has even been linked to the metabolic syndrome itself 
(REF). The male subjects in the milk group had a fairly high ratio at baseline (0.97) 
and this reduced after six months (0.92), albeit non-significantly. The women had a 
low mean ratio both before and after the intervention (0.79 versus 0.67). It is difficult 
to draw any conclusions from this observation in this study, as there was no 
significant increase in saturated fatty acids. 
The limited effect on serum cholesterol might in part be related to the choice of dairy 
products. The Norwegian study population significantly increased the intake of total 
milk (fluid milk and yoghurt combined) and cheese, but there was only a tendency to 
a difference in intake of butter compared to the control group. In the Nordic study, the 
consumption of milk and cheese increased. Butter, which has a higher concentration 
of milk fat than any other dairy product, seems to have a more pronounced 
cholesterol-elevating effect than does a corresponding amount of fat from cheese (98-
100). Maybe the increased intake in cheese in the Norwegian milk group has buffered 
the potential cholesterol-elevating effect of butter. Additionally, the lower-fat dairy 
products as opposed to higher fat alternatives, may have contributed to the lack of 
effect on cholesterol levels.  
Although the intervention meant introduction of many different milk products 
including fermented products (such as yoghurt), which in some earlier studies (92,93) 
have shown a potential hypocholesterolaemic effect, we found no significant increase 
in intake of fermented products (i.e. yoghurt) in the Norwegian milk group. This 
explains the lack of a hypocholesterolaemic effect in our study.  
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6.4.4 Insulin resistance  
We found a difference regarding changes in the HOMA index, an indicator of insulin 
resistance, between the groups. This was most likely, however, due to chance, 
because the main change was an unexpected increase in the control group, whereas no 
change was seen in the milk group. Furthermore, due to the fact that a range of 
statistical tests were carried out, it is highly likely that there will be a significant result 
when the analysis is not adjusted by Bonferroni. Aging per se has no effect on insulin 
sensitivity, independent of changes in body composition (122). Changes in the 
HOMA index were unrelated to those of 15:0 and, thus, were presumably not related 
to changes in milk fat intake. Earlier controlled intervention studies have shown an 
inverse relation between saturated fat intake and insulin sensitivity (84,86). In these 
studies the diets were controlled and the difference in saturated fat intake between the 
test diets, mainly due to a difference in butter fat intake, was larger.  
6.4.5 Inflammation, endothelial function and oxidative stress 
In women only in the Nordic study, there was a significant increase in leptin during 
the milk period, and the individual changes in leptin were positively related to the 
changes in 15:0 in the cholesteryl esters (P = 0.019), which suggests an association 
with dairy fat or some factor related to dairy fat intake. Whether an increased leptin 
concentration, in association with an unchanged body fat mass, might indicate a 
beneficial effect or is a sign of increased leptin resistance is a matter of speculation 
(123). 
An increased proportion of saturated fatty acids in the diet have been related to 
impaired vascular function (124,125) and markers of inflammation (126). The 
relatively small and non-significant increase in the intake of fat, and specifically of 
saturated fat, may explain why there were no changes in markers of inflammation or 
oxidative stress or indications of impaired endothelial function.  
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However, the women showed a significant reduction in plasma VCAM (P = 0.001). 
Whether the changes in leptin and VCAM, seen only in women in the Nordic study as 
a whole, indicate a sex difference in response to an increased intake of dairy products 
remains to be clarified.  
One study has found an association between high cheese consumption and lower 
levels of PAI 1 in women (59,98), however, the PAI-1 levels did not change 
significantly in the Norwegian milk group in the present study, and the cheese intake 
could not be characterized as being high (mean intake 36 g/day ± 23).  
There is some research to indicate that some inflammatory markers do improve with 
increased intake of dairy products, regardless of changes in body weight, this was 
observed for CRP and adiponectin in a study by Zemel et al. in 2008 (127), however, 
these markers did not change in this Norwegian study. 
6.5 Strengths and limitations  
6.5.1 Strengths 
The strengths include the controlled and randomized design, the follow-up of dietary 
compliance during the study by the use of the gold-standard weighed dietary intake, 
and the use of a validated dietary marker in plasma to monitor the dairy fat intake. We 
also used the gold standard method for analysing body composition, the DEXA scan. 
The study is also strengthened by the large amount of advanced laboratory analyses. 
The study was designed to reflect dietary, and related physiologic, changes caused by 
an increased intake of dairy products in a realistic setting. This type of dietary 
intervention, in which no instructions were given regarding energy restriction or other 
dietary changes, giving it a high external validity, is today rare and needed.  
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6.5.2 Limitations 
Among the limitations were the relatively short intervention period of only 6 months 
and the fact that assessment of dietary compliance, apart from the dairy fat intake, was 
based on self-reported dietary records (128). One may also argue that our population 
had a fairly high baseline intake of dairy products and that the increase in the milk 
group was moderate. The sample size of this Norwegian study was also rather small. 
The inclusion of participants from 3 countries with partly different background diets 
in the Nordic study population may be strength of the Nordic study as a whole, but it 
may also complicate the analysis of the dietary and nutrient intake as the food choices 
and food culture and not least the composition of the food items differ. So, for this 
Norwegian study, the dietary analysis is less complicated due to the fact that 
participants are from the same area with access to the same food items, although the 
culture and preferences may differ between the individuals. 
Future studies may benefit from controlling and defining the dairy intake in more 
detail to allow for ease of analysis and the overall food intake must be evaluated 
precisely, maybe even to a greater extent than in this study, by using longer periods of 
weighed intake, or by providing all food products items for the subjects.  
Another aspect of the study which may explain the lack of effect of the intervention 
was the inclusion criteria chosen. May the subjects included have been too healthy for 
an effect to be shown? The average number of metabolic syndrome criteria fulfilled 
was 2.5 and the most frequently fulfilled criteria were enlarged waist circumference 
and increased blood pressure. The average plasma glucose levels, and HDL 
cholesterol levels were normal, TGs only slightly elevated. One may therefore 
speculate that the changes would have been larger if the subjects had had more 
metabolic abnormalities at baseline and, if the sample size had been larger.  
It is interesting how little the overall dietary intake changed during the study. One 
possible explanation for this may be the fact that this was a study situation and the 
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subjects were compliant with the protocol and thus were conscious of not changing 
the overall diet to a large extent.  
Milk drinking and intake of dairy products are in many places around the world 
associated with better health and a healthier lifestyle; such as avoidance of smoking, 
moderate alcohol consumption, regular exercise and higher social class (94). Another 
limitation of this study is therefore the fact that these factors were not all adjusted for 
and not thoroughly evaluated at baseline, although the subjects were instructed to 
maintain their normal exercise level and lifestyle. This may have influenced the 
results. 
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7. Conclusion and future perspective 
Although this study cannot verify any clear effect of an increased dairy intake on 
obesity and blood pressure, it cannot be excluded that such an effect might exist after 
longer intervention periods of maybe as much as several years and/or if there was a 
larger difference in intake between the groups. The absence of changes in body 
weight or body fat during six months suggests the possibility of some restrictive effect 
on body fat accumulation of an increased intake of milk products. Also, the effect on 
waist circumference in subjects in the milk group with a low habitual intake of 
calcium gives some support to the hypothesis of a possible threshold effect. Thus, it 
cannot be excluded that an effect on body composition might be seen in a population 
with a lower intake of dairy products at baseline.  
This study does not have an immediate or direct impact on any dietary 
recommendations. However, the study is of value for future research in this field and 
does indicate that there is a need for larger and longer intervention studies to evaluate 
the value of dairy products in a healthy diet for individuals with the metabolic 
syndrome especially, and for a health promoting diet in general. The inclusion of low-
fat dairy products as part of a healthy diet as is recommended at present, still has its 
place. However, it may be of benefit to further advice individuals with the metabolic 
syndrome of the overall dietary composition with specific emphasis on which other 
foods to reduce when introducing or increasing dairy product intake.  
This study was not, due to the small sample size, capable of discovering clinical 
significant effects of this intervention. The dairy intake in this study was not large 
enough to find positive metabolic effects among subjects with only 2.5 criteria for 
metabolic syndrome fulfilled. In a future perspective, this may imply that to unravel 
the potential metabolic effects of clinical importance a larger sample size is needed, 
and possible larger intakes of dairy products are required. However, such a diet may 
be difficult to achieve within a normal diet in a realistic setting. Moreover, there is a 
potential for an increase in LDL cholesterol with a higher dairy and saturated fatty 
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acid intake and subsequently increased risk of CVD. This must therefore be 
thoroughly deliberated. 
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